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ABSTRACT
 Colorectal Cancer (CRC) is the third-most common malignancy for men or women, 
with chronic inflammation considered as a primary risk factor.  Obesity is also considered 
a chronic inflammatory disease and is associated with increased CRC incidence.  Further, 
obesity and CRC occur in men and women differently with the highest incidence of either 
disease found in men, suggesting that female sex hormones may play a protective role in 
inflammatory diseases.  Macrophages can promote inflammation and are a driving force in 
obesity-associated metabolic dysfunction.  Conversely, macrophages also contribute to 
pro-tumoral responses including, proliferation, angiogenesis and tissue remodeling.  This 
heterogeneity of macrophage behavior and function within these diseases encourages the 
need for macrophage targeted studies.  Currently, the specific role of macrophages 
throughout the initiation and progression of these diseases remains unclear.  Utilizing 
clodronate liposomes to target macrophages, we have uncovered that during late stage 
CRC, macrophage depletion is effective at reducing tumor-promoting macrophage 
signaling that contributed to reduced tumor burden and a more beneficial microbial 
composition.  However, clodronate mediated macrophage depletion was ineffective at 
rescuing obesity induced insulin resistance due to compensatory neutrophil associated 
inflammation.  In addition, we examined macrophage behavior within obesity driven CRC.  
Using a subcutaneous tumor model following diet induced obesity, we found that both 
insulin resistance and tumor growth presented differently in males, females and 
ovariectomized (OVX) females.  Interestingly, the most severe obesity enhanced tumor 
vi 
growth was found in the obese OVX mice.  This was consistent with increased M2-like 
tumor associated macrophages, increased subcutaneous adiposity and enhanced 
macrophage associated adipose tissue inflammation compared to obese females.  These 
results suggest a protective role of female sex hormones in obesity enhanced CRC which 
is potentially mediated by macrophage associated inflammation.  Taken together, our 
findings confirm a unique role of macrophages and macrophage associated inflammation 
in CRC, obesity and obesity-enhanced CRC.  These findings are significant in further 
elucidating macrophage behavior through the progression of inflammatory driven diseases 
and contribute to the mechanistic understanding of sex disparities in obesity associated 
CRC.
vii 
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CHAPTER 1 
INTRODUCTION
2 
Macrophages are major players in the inflammatory response and are not only the 
most abundant immune population in a tumor microenvironment, but also are a driving 
force in obesity-associated inflammation leading to metabolic dysfunction.  Macrophages 
are considered highly plastic immune cells and can assume a variety of functions according 
to their environment.  They can be generally categorized into two broad but distinct subsets 
as either, classically activated (M1), which are pro-inflammatory/anti-cancer or 
alternatively activated (M2), which are anti-inflammatory/pro-cancer.  However, recent 
evidence suggests macrophages exist on a spectrum of diverse phenotypic states rather than 
the rigid dichotomy of M1/M2 phenotypes[1]. Such heterogeneity of macrophage behavior 
provides uncertainty regarding the role of macrophages in the progression of certain 
chronic inflammatory diseases.  This led us to explore the role of macrophages and 
macrophage associated inflammation in chronic inflammatory diseases: obesity, colorectal 
cancer (CRC) and obesity enhanced-CRC.  
 
1.1 Macrophages in Chronic Inflammation 
Chronic inflammation is a prolonged condition in which tissue injury and repair 
simultaneously occur, leading to tissue remodeling and dysfunction.  Chronic inflammation 
often begins as a low-grade, smoldering response which lacks the cardinal signs of 
inflammation; pain, heat, redness and swelling[2]. Moreover, the continuous progression 
of tissue injury and repair promotes extensive fibrosis that may eventually cause 
irreversible tissue dysfunction.  This persistent low-grade inflammation has been found 
responsible for promoting many diseases, specifically obesity associated insulin resistance 
and CRC[3-5].  
3 
Macrophages can enter various tissues in response to chronic inflammation and 
assume different functions and phenotypes according to the cues they receive from the 
environment[6]. The infiltration of macrophages within tissues is controlled, in part, 
through the monocyte chemoattractant protein-1 (MCP-1)[1]. Upon entering the tissue in 
response to MCP-1, pro-inflammatory cytokines such as IFN-γ, TNF, or Toll-like receptor 
(TLR) ligands, encourage an M1 phenotype while M2 phenotype is promoted upon IL-4, 
IL-10, or TGF-β stimulus.  M1 macrophages release high levels of pro-inflammatory 
cytokines, including tumor necrosis factor-α (TNF-α), MCP-1, IL-6, and inducible nitric 
oxide synthase (iNOS) [7]. On the contrary, M2 macrophages have been demonstrated to 
express high levels of mannose receptor (CD206), and produce a large amount of IL-10, 
and arginase-1[8, 9]. In the context of chronic inflammation, the ratio between M1 and M2 
macrophages is constantly shifting during bouts of inflammation followed by periods of 
tissue healing.  This fluctuation in macrophage subsets throughout the progression of 
chronic inflammation makes it unclear which macrophage subsets are truly responsible for 
disease progression. 
 
1.2 Inflammation induced colorectal cancer 
Colorectal cancer is the third most prevalent cancer as well as the third leading 
cause of cancer related deaths.  Although, direct etiology is uncertain, there is an increased 
risk of colorectal cancer within individuals suffering from chronic inflammatory diseases, 
particularly, inflammatory bowel diseases (IBD).  As discussed previously, macrophages 
can strongly influence both the onset of inflammation within the colon and conversely, 
promote tissue remodeling, which can support dysplasia.  The intestine is the largest 
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reservoir of macrophages in the body [10] where they have a close relationship with 
luminal bacteria. [11] Under inflammatory conditions, monocytes are recruited to the 
lamina propria and become inflammatory macrophages that secrete cytokines. [12] This 
macrophage-induced inflammation mediates many pro-tumoral responses.  [13-18] Thus, 
it is no surprise that macrophages have been implicated in tumorigenesis given their 
propensity to promote inflammation.  [18-30]  
Although M1 macrophages are heavily involved in initiating colon inflammation, 
the resulting M2 macrophage mediated tissue remodeling can trigger tumor growth.  
Within this tumor microenvironment, macrophages are the most abundant immune 
population.  Tumor derived factors such as TGF-β and IL-10 have the potential to polarize 
infiltrating monocytes mainly into a M2-like phenotype that can then further promote 
proliferation, invasion and metastasis, angiogenesis, and matrix deposition and remodeling 
[31]. These macrophages are referred to as tumor-associated macrophages (TAMs).  The 
majority of studies have reported that high levels of TAMs are associated with poor 
prognosis in CRC [32, 33], with just a few reports indicating an association between 
macrophage infiltration and increased survival [34, 35]. A crosstalk between TAMs and 
cancer cells enhances production of inflammatory cytokines, chemokines, proteases, 
growth factors and angiogenesis-related factors [31].  Additionally, these substances 
transform the tumor microenvironment to favor the survival, growth and motility of cancer 
cells.  Thus, macrophage-induced inflammation mediates many of the pro-tumoral 
responses in the tumor microenvironment [13-18].  Given macrophages strong presence 
within the tumor microenvironment, targeting TAMs can offer beneficial effects for 
inflammation driven cancers.  
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1.3 Obesity associated inflammation and insulin resistance 
Obesity is considered an epidemic and affects more than 1/3 of the U.S. population.  
It is largely defined by two primary characteristics: chronic, low-grade inflammation and 
metabolic dysfunction.  It is believed that the main driving force behind the development 
of type 2 diabetes and insulin resistance is inflammation, particularly macrophage 
associated inflammation [36]. Infiltrating immune cells are primarily pro-inflammatory 
macrophages, otherwise classified as M1 macrophages which are responsible for adipose 
tissue inflammation [37].  Under obese conditions, M1 macrophages may account for 
approximately 50% of all adipose tissue cells [37].  Conversely, in the lean condition, 
macrophages only account for approximately 10% of all adipose tissue cells, with the anti-
inflammatory, M2 macrophage phenotype being the most predominant.  During the onset 
of obesity, the macrophage presence within adipose tissue shifts from M2, which helps 
promote homeostasis through efferocytosis, angiogenesis promotion and lipid buffering 
toward a more M1 dominant phenotype which increases production of inflammatory 
cytokines and reactive oxygen species resulting in non-esterified fatty acid release [38]. 
More specifically, M1 adipose tissue macrophages secrete the pro-inflammatory cytokines, 
TNFα, IL-6 and IL-1β, which act as main effectors of impaired adipocyte function and 
have been shown to reduce insulin sensitivity in certain tissues [37, 39-41]. Therefore, 
targeting macrophage-associated inflammation may offer potential benefits in preventing 
or delaying obesity induced insulin resistance.  
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1.4 Sex-Disparities in Obesity-Enhanced Colorectal Cancer.  
A sex-specific effect is present in the incidence of obesity in CRC patients.  Several 
epidemiological studies have demonstrated that obesity increases the risk of and mortality 
from CRC in males [42-44].  The relationship in females is somewhat inconsistent, in part 
due to a potential protective effect that reproductive hormones have on CRC.  In 
postmenopausal women however, this effect may be limited to individuals not currently 
using hormone replacement therapy (HRT) [45].  A protective effect of HRT on colon 
cancer has been reported in several epidemiological studies [46, 47]. Taken together, these 
studies suggest that a woman’s risk of colon cancer is affected by hormonal status.  Despite 
these findings, the mechanisms linking estrogen and/or progestins to reduced cancer risk 
have not been fully elucidated.  
The role of estrogen in macrophage polarization under physiological conditions 
remains unclear.  There is evidence that estrogen inhibits the production of Th1 cytokines, 
while stimulating the production of Th2 cytokines [48]. In this case Th2 cytokines 
generally promote M2 macrophage polarization however there is little evidence to support 
a direct effect of estrogen on macrophage polarization.  Taken together, current literature 
does not provide a conclusive role for estrogen in CRC and calls for more research to better 
understand the mechanism behind this suspected protection.  Given the influential role of 
macrophages in chronic inflammatory diseases and differential incidence within males and 
females, further investigation to test if estrogen has some influence on macrophage 
behavior is warranted.   
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1.5 Summary 
Macrophages play a variety of roles during the development of chronic 
inflammation leading to disease.  In the context of obesity, M2 adipose tissue macrophages 
are most abundant in the lean state but as obesity progresses M1 adipose tissue 
macrophages predominate. These M1 macrophages are thought to drive inflammation 
induced insulin resistance.  Conversely in the context of inflammation associated CRC, 
intestinal macrophages are more M1 in the early stages of inflammation but during later 
stages as tumors begin to form, M2 like TAMs predominate which is associated with poor 
prognosis.  There is further evidence to support that sex disparities within these 
inflammatory diseases, may be, in part, associated with sex hormones influence on 
macrophage behavior.  Therefore, the overall goal of this research is to examine the role of 
macrophages in CRC and risk factors associated with CRC including obesity and sex.  The 
central hypothesis is that macrophage associated inflammation enhances progression of 
CRC and this can be exacerbated among obese populations.  Further, it is hypothesized that 
macrophage associated inflammation may contribute to the sex disparities observed in 
obesity and CRC.  This hypothesis was tested by pursuing three research aims: 1) to 
determine the effect of macrophage depletion on intestinal inflammation, the gut 
microbiota profile, and colon tumorigenesis [49]; 2) to determine the effect of macrophage 
depletion in diet induced obesity associated inflammation and metabolic dysfunction [50]; 
and 3) to examine sex-specific differences as they relate to macrophage behavior in 
obesity-enhanced CRC. 
The purpose of the first study was to examine the role of macrophages in 
progression of CRC while also considering the interaction between macrophages and gut 
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microbiota in CRC.  This was done using the chemically-induced, azoxymethane (AOM) 
and dextran sodium sulfate (DSS), model of CRC.  In this AOM/DSS model animals 
develop tumors following three cycles of a colon irritant, resembling inflammation induced 
CRC, such as in IBD patients.  We used clodronate filled liposomes to deplete macrophages 
during the late stage (week 7) of this model in order to specifically target TAMs rather than 
inflammatory macrophages within the early stages [51-53].  
 In the second study, we sought to examine the role of macrophage associated 
inflammation in obesity induced insulin resistance.  Utilizing HFD feeding, an obese 
phenotype was established prior to depleting macrophages with clodronate encapsulated 
liposomes, in order to determine if macrophage depletion could serve as an effective 
intervention to reduce obesity-driven adipose tissue inflammation and to ameliorate 
metabolic dysfunction. 
 In the final study, sex differences in obesity enhanced colorectal cancer were 
examined.  Diet induced obesity was established in male, female, and ovariectomized mice, 
prior to injection of MC38 colon cancer cells subcutaneously.  Tumor associated 
macrophage phenotype and macrophage associated adipose tissue inflammation were 
examined to better understand the role of macrophages in sex specific effects on diet 
induced obesity.  
Taken together, the studies described offer unique insight into the differential role 
that macrophages play in the chronic inflammatory driven diseases of obesity and CRC.  
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CHAPTER 2 
 
MACROPHAGE DEPLETION USING CLODRONATE LIPOSOMES 
DECREASES TUMORIGENESIS AND ALTERS GUT MICROBIOTA IN 
THE AOM/DSS MOUSE MODEL OF COLON CANCER1 
 
 
 
 
 
 
 
1Bader JE, Enos RT, Velázquez KT, Carson MS, Nagarkatti M, Nagarkatti PS, 
Chatzistamou I, Davis JM, Carson JA, Robinson CM, Murphy EA. Macrophage depletion 
using clodronate liposomes decreases tumorigenesis and alters gut microbiota in the 
AOM/DSS mouse model of colon cancer. Am J Physiol Gastrointest Liver Physiol. 2018 
Jan 1;314(1):G22-G31  
 Reprinted here with permission from publisher 
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2.1 Abstract  
We examined the role of macrophages in inflammation associated colorectal cancer 
(CRC).  Given the emerging evidence on immune-microbiota interactions in CRC, we also 
sought to examine the interaction between macrophages and gut microbiota.  To induce 
CRC, male C57BL/6 mice (n=32) received a single injection of azoxymethane (AOM) 
followed by three cycles of dextran sodium sulfate (DSS) supplemented water at weeks 1, 
4, and 7, respectively.  Prior to the final DSS cycle (week 7) and twice weekly until 
sacrifice, mice (n=16/group) received either 200l i.p. of clodronate filled liposomes 
(CLD) or phosphate buffered saline (PBS) encapsulated liposomes to deplete 
macrophages.  Colon tissue was analyzed for polyp burden, macrophage markers, 
transcription factors, and inflammatory mediators.  Stool samples were collected and DNA 
was isolated and subsequently sequenced for 16S rRNA.  Clodronate liposomes decreased 
tumor number by ~36% and specifically large (≥1mm) tumors by ~36% (p<0.05).  This 
was consistent with a decrease in gene expression of EMR1 in the colon tissue and polyp 
tissue as well as expression of select markers associated with M1 (IL-6) and M2 
macrophages (IL-13, IL-10, TGFβ & CCL17) in the colon tissue (p<0.05).  Similarly, there 
was a decrease in STAT3 and MAPK p38 and ERK signaling in colon tissue.  Clodronate 
liposomes increased the relative abundance of the Firmicutes phylum (p<0.05) and 
specifically Lactobacillaceae and Clostridiaceae families, which have been associated 
with reduced CRC risk.  Overall, these data support the development of therapeutic 
strategies to target macrophages in CRC and provide support for further evaluation of 
immune-microbiota interactions in CRC.   
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2.2 Introduction 
Colorectal cancer (CRC) is the third most common malignancy for men or women.  
For CRCs detected in stage I there is a 91% survival rate whereas that drops to 11% if the 
cancer is detected in stage IV [54]. As CRC progresses, treatment options become more 
limited and some patients with advanced CRC opt for no treatment given the lack of 
success of current therapies.  Immunotherapy is a relatively recent strategy that has had 
some success in treating patients with advanced CRC.  However, current immunotherapy 
options are limited.   For example, Pembrolizumab, an immune checkpoint inhibitor 
targeting PD-1 is limited to patients that have tested positive for specific gene changes [55].  
There is a critical need to develop new immunotherapy-based strategies for treatment of 
CRC. 
Macrophages are the most abundant immune population in a tumor 
microenvironment.  They are derived from monocytic precursors circulating in blood and 
are recruited to the tumor site by chemokines such as MCP-1 and TGFβ [56, 57]. These 
recruited monocytes differentiate into mature macrophages within the tumor 
microenvironment.  While historically it was thought that macrophages possess anti-tumor 
functions it is now generally accepted that tumor associated macrophages (TAMs) are 
conditioned by the tumor environment and exert pro-tumoral functions.  Factors such as 
TGF-β and IL-10 have the potential to modulate and polarize monocytes mainly into M2 
macrophages that can then promote proliferation, invasion and metastasis, angiogenesis, 
and matrix deposition and remodeling [31].  The majority of studies have reported that high 
levels of TAMs are associated with poor prognosis in CRC [32, 33] with just a few reports 
indicating an association between macrophage infiltration and increased survival [34, 35]. 
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Understanding the importance of macrophages in CRC is likely to have significant 
therapeutic implications. 
Increasing evidence implicates gut microbiota in the initiation and progression of 
CRC [58]. Mechanistic support for this relationship comes from animal studies; germ-free 
status and treatment with wide-spectrum antibiotics results in a significant reduction in 
CRC [59, 60]. In humans, CRC-associated microbiome risk profiles have been generally 
characterized as changes in certain microbe abundance and/or changes in microbial 
diversity.  Recent discoveries suggest that immune cells play a pivotal role in this response.  
For example, host-derived inflammatory responses are important driving forces that shape 
microbial community composition and, when altered, may contribute to dysbiosis and 
increased CRC risk [61-63]. Conversely, gut microbes also can influence immune 
responses in the colon.  A recent study reported that germ-free mice exhibit decreased 
populations of intestinal regulatory T cells [64].  Similarly, antibiotic treatment in mice 
resulted in reduction of Th17 cells within the colon [65].  Despite the increasing evidence 
supporting an immune-microbiota interaction in CRC, there are no studies that have 
directly examined the role of macrophages on gut microbiota in a model of CRC. 
The purpose of this study was to examine the role of macrophages in progression 
of CRC.  We also sought to examine the interaction between macrophages and gut 
microbiota in CRC.  This was done using a chemically-induced model of CRC, namely the 
azoxymethane (AOM) and dextran sodium sulfate (DSS) model.  In this AOM/DSS model 
animals develop tumors due to several gene mutations that are consistent with those seen 
in CRC patients [66].  We used clodronate filled liposomes to deplete macrophages [51-
53].  As we were interested in examining the role of macrophages in progression of 
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tumorigenesis (as opposed to initiation), macrophages were depleted during the last cycle 
of DSS treatment (i.e. late stage at a time when tumors are already present as confirmed by 
our laboratory (unpublished)).  Our data indicate that clodronate administration during late 
stage tumorigenesis results in a decrease in polyp number, reduced expression of select 
macrophage markers, diminished activation of transcription factors known to regulate 
carcinogenic processes, and alterations in the gut microbiota profile. 
 
2.3 Materials and Methods 
Animals and AOM/DSS model: C57BL/6 (wild-type (WT)) male mice (n=32) were 
purchased from Jackson Laboratories.  All experimental mice were fed an AIN-76A diet 
(Bio-serv) and were provided with water ad libitum for the duration of the experiment.  At 
8-10 weeks of age, all mice were injected i.p. with a single dose of 10 mg/kg of AOM 
(Sigma) designated as week 0.  DSS (MP Biochemicals; 36,000-50,000 mw) was dissolved 
in filtered drinking water and administered to mice for 7 days during the following weeks: 
1 (2% DSS), 4 (1% DSS), and 7 (1% DSS).  To deplete macrophages, we administered a 
200ul i.p. injection (~1mg) of clodronate encapsulated liposomes (ClodronateLiposomes, 
Amsterdam, The Netherlands) beginning at week 6.5 and continuing twice weekly until 
sacrifice (CLD).  This dose was selected based on the recommendations of the 
manufacturer and previously published literature.  Phosphate buffered saline (PBS) 
encapsulated liposomes (ClodronateLiposomes) were administered in the same manner to 
the vehicle control group (VEH).  After 12 weeks, mice (VEH & CLD) were sacrificed, 
colon contents were collected for microbiota profiling, colons were dissected, and polyps 
were counted using a stereoscope.  For a subset of samples (n=4-8) the distal portion of the 
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colon was fixed in 4% paraformaldehyde, paraffin embedded, and sectioned for 
Hematoxylin & Eosin (H&E) staining.  Polyps were removed from the remaining colon 
tissue and flash frozen for RT-PCR analysis.  The remaining colon tissue was then divided 
into two pieces for western blot and RT-PCR analysis.  The Institutional Animal Care 
Committee of the University of South Carolina approved all the animal experimentation.    
Morphometric measurements, food and water intake:  Body weight, and food and 
water intake were monitored weekly over the duration of the experiment.  Body 
composition was assessed before AOM injection and prior to sacrifice (week 12) via dual-
energy x-ray absorptiometry (DEXA, Lunar PIXImus) as previously described [67]. 
Symptom Severity: Symptom score was evaluated twice a week beginning at the 
first cycle of DSS exposure.  Briefly, animal health was monitored by combining the scores 
of weight loss (WL) (>5%WL=0; 6-10%WL=1; 11-15%WL=2); fecal consistency 
(pellet=0; pasty=2; liquid=4); and blood in stools (assessed with hemoccult kit negative=0, 
positive=2, and gross bleeding=4) [68].  
Gene expression: Quantitative RT-PCR (ABI-7300) was performed in both the 
polyp and colonic tissue after RNA isolation with trizol reagent and purification from DSS-
treated tissues as described in detail [69].  Sample ct values calculated as relative to 18S 
rRNA internal control and normalized to vehicle control.  The following Taq primers from 
Applied Biosystems were used: MCP-1, TNFa, IL-6, EMR1, NOS2, IL-10, IL-12a, IL-23, 
IL-13, TGFb, Arg1, and CCL17. 
Western blot analysis:  The frozen colons were homogenized in mueller buffer [70] 
and total protein was determined via the Bradford method.  All samples were run in 
triplicate on the same plate with a CV of less than 3%.  Equal amounts of crude protein 
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homogenates (10-40 μg) were fractioned on hand-casted 6.5-12% SDS-polyacrylamide 
gels and electrophoretically transferred to a PVDF membrane using a Genie Blotter (IDEA 
Scientific, Minneapolis, MN).  Membranes were stained with a Ponceau S solution to 
verify equal protein loading and transfer efficiency.  Subsequently, membranes were 
blocked for one hour in 5% milk in Tris-buffered saline, 0.1% Tween-20 (TBST).  Primary 
antibodies were diluted 1:1,000 in 5% milk-TBST or 5% BSA-TBST solution according 
to antibody specifications for either a 1 hour incubation at room temperature [Cell 
signaling, Danvers, MA: total ERK (#4676) total Stat 3 (#4904) and total p38 (#8690)] or 
overnight incubation at 4C [Cell signaling: total (#8242) and phosphorylated (Ser536) 
NFκB p65 (#3033), phosphorylated (Thr180/Tyr182) p38 (#4631), phosphorylated ERK 
(#4376), phosphorylated Stat 3 (y705) (#9138)].  An anti-rabbit (Cell signaling: #7047) or 
anti-mouse (Cell Signaling: #7076) IgG horseradish peroxidase conjugated secondary 
antibody was diluted 1:2000 in 5% milk and incubated for one hour at room temperature.  
An enhanced chemiluminescent substrate for detection of horseradish peroxidase (Thermo 
Scientific, Watham, MA) was used to visualize the antibody-antigen interaction.  
Autoradiography films were scanned and blots were quantified using scientific imaging 
software (Image J).  After completion of the western blot, all membranes were stained with 
Amido black, and the densitometry of each lane was calculated using Quantity One 
Software (Bio-Rad, Hercules, CA) allowing for total protein normalization.  This method 
of normalization has been shown to be more accurate than typically used loading controls 
[71]. 
Histology: Paraffin block sections of the distal colon were stained with H&E and 
subsequently evaluated blindly by a pathologist (I.C.) and characterized according to the 
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severity of tumor dysplasia when a tumor was present in the section; low-grade dysplasia 
(LGD) or high-grade dysplasia (HGD). 
Microbiome Analysis: Following sacrifice, feces from the colon was removed, snap 
frozen and stored at -80°C until analysis.  Microbial DNA was isolated from feces using a 
QIAamp Fast DNA Stool Mini Kit (QIAGEN #51604) according to manufacturers’ 
instruction.  The DNA concentration was determined using a Nanophotometer Pearl, 
diluted to 5 ng/ul in 10 mM Tris Buffer pH 8.5 and stored at -20°C until analysis.  
Amplification of the 16S rRNA V3-V4 hypervariable region was carried out using the 16S 
V3 314F forward 
(5′TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG
3′) and V4 805R reverse primer 
(5′GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCT
AATCC3′) with added Illumina adapter overhang nucleotide sequences [72]. The PCR 
conditions used were 3 min at 95 °C followed by 25 cycles of 30 s at 95 °C, 30 s at 55 °C 
and 30 s at 72 °C, and a final extension at 72 °C for 5 min.  Each reaction mixture (25 μl) 
contained 50 ng of genomic DNA, 0.5 μl of amplicon PCR forward primer (0.2 μM), 0.5 
μl of amplicon PCR reverse primer (0.2 μM) and 12.5 μl of 2× KAPA Hifi Hot Start Ready 
Mix. Each reaction was cleaned up using Agencourt AMPure XP beads.  Attachment of 
dual indices and Illumina sequencing adapters was performed using 5 μl of amplicon PCR 
product DNA, 5 μl of Illumina Nextera XT Index Primer 1 (N7xx), 5 μl of Nextera XT 
Index Primer 2 (S5xx), 25 μl of 2× KAPA HiFi Hot Start Ready Mix, and 10 μl of PCR-
grade water.  Amplification was carried out under the following conditions: 3 min at 95 
°C, followed by 8 cycles of 30 s at 95 °C, 30 s at 55 °C, and 30 s at 72 °C, and a final 
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extension at 72 °C for 5 min. Constructed 16S metagenomic libraries were purified with 
Agencourt AM Pure XP beads and quantified with Quant-iTPicoGreen. Library quality 
control and average size distribution were determined using an Agilent Technologies 2100 
Bioanalyzer.  Libraries were normalized and pooled to 40 nM based on quantified values.  
Pooled samples were denatured and diluted to a final concentration of 6 pM with a 30% 
PhiX (Illumina) control.  Amplicons were subjected to pyrosequencing using the MiSeq 
Reagent Kit V3 in the Illumina MiSeq System. 
The online 16S analysis software from NIH (https://nephele.niaid.nih.gov/) was used to 
analyze sequencing data collected on the Illumina Miseq.  FASTQ sequences were 
uploaded to Nephele and the 16S metagenomics application was executed.  The groups of 
related DNA sequences were assigned to operational taxonomic units (OTUs), and output 
files were analyzed to determine gut microbial composition. 
Statistics:  Data were analyzed using commercially available statistical software: 
Prism 5 and SigmaStat (GraphPad Software).  Data were analyzed using an unpaired 
Student t-test or Fisher’s exact test (categorical data).  Any statistical test that did not pass 
the equal-variance test (Bartlett’s test for equal variances) was log transformed and then 
re-analyzed.  Data are presented as the mean ± SEMs and the level of significance was set 
at p<0.05.  
 
2.4 Results 
Effects of clodronate administration on morphometric characteristics in AOM/DSS treated 
mice.  
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Body weights and symptom scores over the course of the 12-week AOM/DSS 
protocol are presented in Figure 2.1. The dashed line represents the initiation of clodronate 
treatment at week 6.5 and twice weekly i.p. injections for the duration of the study.  There 
was no difference in body weight between treatment groups prior to clodronate 
administration; however, body weight was reduced in clodronate treated mice following 
administration at weeks 7-12 (p=0.079, 0.066, 0.015, 0.023, 0.002, and 0.007 respectively 
(Figure 2.1A)).  Despite the decrease in body weight, there was no significant difference 
in symptom scores between treatment groups over the course of the experiment (Figure 
2.1B).  It is important to note that mice from each treatment had similar starting body 
weights (p=0.218) ensuring that both groups received similar doses of the carcinogen AOM 
(Figure 2.1A).  Additionally, both groups consumed equal amounts of total DSS over the 
course of the 12-week protocol (p=0.923) (data not shown).  Regarding food intake, 
clodronate treatment significantly decreased consumption compared to control mice and 
this was consistent with a decrease in lean mass, fat mass and fat% in the DEXA body 
composition measurements (Figure 2.1 C-E).  
Effects of clodronate administration on colon polyps and colon inflammation 
Clodronate administration resulted in a significant reduction in overall polyp 
number (p=<0.001).  When polyps were stratified by size, we found a reduction in large 
polyps greater than or equal to 1 mm (p=0.012) and a slight, but non-significant, reduction 
in small polyps less than 1 mm (p=0.100) following clodronate treatment (Figure 2.2A-B).  
Following histological analysis, we did not document any colon carcinomas in either 
group.  However, it should be noted that only the distal colon was included in this analysis 
and for a small subset of mice (n=4-8).  To further explore the effects of clodronate 
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administration on tumorigenesis, distal colon polyps were evaluated for dysplasia and 
quantitatively represented as low-grade dysplasia (1) or high-grade dysplasia (2).  There 
was no significant difference in severity of dysplasia between treatment groups with both 
groups exhibiting high-grade dysplasia in polyps scored (Figure 2.2C-D).  Similarly, 
histological inflammation revealed no differences between the groups.  To further evaluate 
the CRC phenotype, spleen and colon weight and colon length to width ratio were 
determined.  The ratio of spleen to body weight and colon weight was reduced in the 
clodronate treated group (p=0.007 and 0.152 respectively), which is consistent with the 
decreased tumor number (Figure 2.2E-F).  However, there was no difference in the colon 
length to width ratio (Figure 2.2G).   
Effects of clodronate administration on cytokine and cell marker expression in the colon 
In addition to histological evaluation of the colon, gene expression profiles via 
qPCR of cytokine and macrophage cell markers for both colon and colon polyp tissue are 
shown in Figure 2.3. Within the clodronate treated group, the macrophage cell marker 
F4/80 was significantly reduced in both colon and colon tumor tissue (p=<0.001 and 
p=0.024, respectively) confirming that clodronate was effective at depleting F4/80 positive 
cells in both the target tissue and tumor (Figure 2.3A).  This was consistent with a decrease 
in MCP-1, a strong macrophage chemoattractant, in the colon tissue of clodronate treated 
mice (p=0.019) (Figure 2.3B).  Despite the reduction in the macrophage cell marker F4/80 
and macrophage chemoattractant, we were not able to characterize this decrease as M1 or 
M2 phenotype specific as no statistically significant differences were found for NOS2 and 
Arg 1, M1 and M2 markers, respectively (p=0.643 and p=0.389).  However, within the 
colon tissue, anti-inflammatory M2 associated cytokines including IL-13, TGF-, IL-10, 
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and CCL-17 were significantly reduced (p=<0.001, 0.002, <0.001, and 0.009, respectively) 
with clodronate treatment.  Aside from IL-6 (p=0.01) there were no significant differences 
in pro-inflammatory M1 associated cytokines.  Despite the reduction in F4/80 expression, 
there were no significant differences in macrophage marker or cytokine expression in the 
colon tumors (Figure 2.3C).  To confirm that changes in gene expression are reflective of 
changes in downstream signaling pathways, western blot analysis was performed and 
results are illustrated in Figure 2.4. Consistent with reduced expression of IL-10 and IL-6 
in the clodronate treated group, was activation of the downstream transcription factor 
STAT3 (p=0.026 and 0.005, respectively).  There was also a significant reduction in the 
activated MAPK signaling molecules p38 and ERK for the clodronate treated group 
(p=0.003 and p=<0.001, respectively).  However, there was no significant difference in 
NFKb expression for phosphorylated, total or calculated ratio, between the groups.   
Effects of clodronate administration on microbiota composition 
Stool samples were collected at sacrifice and 16S microbial rRNA sequencing was 
performed (Figure 2.5).  Relative abundance of OTUs in the Firmicutes phylum were 
significantly increased in the clodronate treated group compared with the control group 
(p=0.02) (Figure 2.5A).  Specifically, within the Firmicutes phylum, the Lactobacillaceae 
and Clostridiaceae families were significantly increased in the clodronate treated group 
contributing to the respective changes at the Phylum level (p=0.04 and 0.009, respectively).  
Additionally, there was a slight increase in Erysipelotrichaceae family in the clodronate 
treated group although not statistically significant (p=0.08) (Figure 2.5B).  Despite 
differences in relative abundance within phyla and families, there were no significant 
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differences between alpha or beta diversity, as shown through Chao1 index and weighted 
UniFrac PCA plots, respectively (Figure 2.5C-D).  
 
2.5 Discussion 
TAMs have been associated with CRC progression, metastasis, and poor prognosis 
[33, 73-75].   However, this relationship is complex given that different macrophage 
subsets are likely to have stage-specific roles in CRC progression.  Using the AOM/DSS 
mouse model of CRC we sought to better understand the role of macrophages in tumor 
progression.  As emerging evidence implicates immune-microbiota interactions in CRC 
we also sought to examine the interaction between macrophages and gut microbiota in 
CRC.  Our data indicate that clodronate administration, a well-established method to 
deplete macrophages [51-53], during late stage tumorigenesis results in a decrease in polyp 
number, reduced expression of select macrophage markers, diminished activation of 
transcription factors, and alterations in the gut microbiota profile. 
We used clodronate liposomes to deplete macrophages during the final cycle of 
DSS (i.e. at a time when polyps are present) to specifically determine their role in tumor 
progression as opposed to tumor initiation.  This approach was employed in order to 
establish the efficacy of targeting macrophages for treatment of CRC.  We report a 
significant reduction in overall polyp number (36%) as well as the number of large polyps 
(36%).  However, as baseline polyps (i.e. prior to clodronate treatment) were not evaluated 
we were not able to determine whether clodronate treatment decreased size of existing 
polyps and/or growth of new polyps.  These findings are consistent with a previous study 
from our laboratory showing that deletion of MCP-1, the most important chemokine for 
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macrophage recruitment, results in a decrease in polyp number and size in in the ApcMin/+ 
mouse model of intestinal tumorigenesis.  Zhao et al., reported similar findings with a 
~45% percent reduction in AOM/DSS induced tumorigenesis when macrophages were 
depleted during both the initiation and progression of tumorigenesis [76].  However, unlike 
the current study, stage-specific effects could not be determined from these reports.  
Despite the differences in polyp number and size, we were not able to detect a difference 
in severity of dysplasia or histological inflammation between treatment groups.  This may 
not be entirely surprising given that clodronate administration was performed at a time 
when mice are likely to already exhibit high dysplasia and this analysis was performed on 
a small sample size.  Similarly, and likely for the same reasons, we were not able to identify 
any differences in disease activity index scores.  Contrary to what would be expected with 
reduced tumorigenesis, the clodronate treated group had a decrease in body weight and 
body fat percent; typically, body weight loss or fat loss is associated with worsened 
outcome in this model.   However, given the fact that tumorigenesis was decreased with 
clodronate and that we (unpublished) and others [77] have found a decrease in food 
consumption and/or body weight with clodronate/macrophage depletion [77, 78], we 
suggest that this is an effect of clodronate treatment independent of the tumorigenesis 
outcomes.  Given this, it is certainly possible that the reduced tumorigenesis associated 
with clodronate treatment could be explained, or partially explained, by the reduction in 
food intake and subsequent decrease in body weight as there is evidence that caloric 
restriction reduces tumorigenesis [79]. Nonetheless we believe that our findings set the 
stage for the development of strategies to target macrophages to treat CRC.   
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Although clodronate liposomes are a well-established method of macrophage 
depletion in the colon [51-53], we wanted to confirm successful depletion in our hands and 
further establish whether it was effective at depleting macrophages in the tumor 
microenvironment.  Indeed, we show that compared to PBS, clodronate-filled liposomes 
successfully decreased expression of F4/80+, a pan macrophage marker, within the colon 
tissue and corresponding polyp tissue (Figure 2.3A); although it appeared more effective 
in the colon tissue.  This is not surprising given the route of administration and mechanism 
of action of clodronate [51-53]; macrophages in the intestinal tissue would likely be more 
available to uptake the liposomes than those deep within the tumor tissue, clodronate does 
not result in complete depletion of macrophages, and there is evidence to suggest that 
TAMs may lose their phagocytic activity as tumorigenesis progresses [80]. To further 
characterize the effects of clodronate on macrophages in the colon and tumor 
microenvironment we examined M1 and M2 macrophage associated markers.  In general, 
and as for F4/80, clodronate liposomes were more effective at altering expression of 
macrophage markers in the colon tissue as opposed to the polyp tissue.  In the colon tissue 
clodronate decreased expression of select M1 (IL-6) and M2 (IL-13, IL-10, TGFβ and 
CCL17) associated markers along with the macrophage chemoattractant MCP-1 indicating 
its non-selectivity for macrophage phenotype.  Thus, a simultaneous/non-specific 
reduction in markers associated with both M1 and M2 macrophage populations can reduce 
tumorigenesis.  Interestingly, we found an increase in IL-13 in the tumor microenvironment 
in the clodronate treated group.  IL-13 has been shown to be increased in certain cancers 
and can influence polarization of TAMs [81, 82].  Therefore, it is possible that the spike in 
IL-13 is compensatory production of IL-13 by T helper 2 cells in response to the overall 
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decrease in F4/80 positive cells.  While we and others have successfully used clodronate 
to deplete macrophages, the possibility of also impacting dendritic cells has been reported 
[51] and these cells can influence CRC [83]. Thus, we cannot rule out a role for dendritic 
cells in this model.  While we did not measure systemic cytokine levels in this study it is 
certainly possible that a reduction in circulating inflammatory mediators by clodronate [84] 
also may be contributing to the reduced tumorigenesis in this model.  Although these 
findings should be validated using FACS, we conclude that clodronate administration has 
beneficial effects on tumorigenesis and that even larger effects may be possible if M2 
macrophages can be selectively depleted in the tumor microenvironment.     
Given the significant effects of clodronate administration on cytokines in the colon 
tissue we next examined downstream transcription factors in the normal tissue.  STAT3, a 
major mediator of IL-6 and IL-10 signaling, was reduced following clodronate treatment 
consistent with the decrease in mRNA expression of IL-6 and IL-10.  STAT3 has been 
reported to be deregulated in many cancers including CRC and has been associated with 
metastasis and poor prognosis [85, 86].  p38 MAPK also was decreased in clodronate-
treated mice.  Although the p38 pathway is often related to pro-apoptotic effects and tumor 
suppressor activity in some tissues, it has been suggested that p38 acquires an oncogenic 
role particularly in established malignancies [87].  Similarly activated ERK MAPK was 
decreased in the clodronate-treated group.  Mutations leading to constitutive activation of 
ERK pathways are found in >40% of CRC patients and significantly contribute to tumor 
formation and progression [87, 88]. In support of our findings, Chiacchiera et. al. has 
shown that combined inhibition of p38 and ERK MAPK pathways efficiently reduces the 
volume of xenografted tumors and AOM/DSS-induced tumors in vivo [88].   On the other 
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hand, there was no change in activated NF-κB with clodronate treatment although NFκB 
has been associated with CRC [89]. The failure to detect a difference in NFκB may not be 
surprising as there was no difference in TNF-α, an activator of the canonical NFκB 
pathway, and IL-1β was not measured.  Alternatively, the failure to see changes in activated 
NFκB may reflect averaging of this signal in whole colon comprised of an admixture of 
cells.  While not performed for the current study given limitations in tissue, it would have 
been useful to double-stain colon sections for both p-NFκB p65 and a macrophage marker 
to determine whether macrophage NFκB signaling is altered.  Even so, these data provide 
strong support for targeting macrophages to prevent the activation of transcription factors 
associated with CRC.   
Emerging evidence implicates immune-microbiota interactions in CRC [90, 
91]. Therefore, we next examined the effects of clodronate treatment on the gut microbiota 
profile.  Relative abundance of OTUs in the Firmicutes phylum was significantly higher in 
the clodronate-treated group.  Firmicutes, represent one of the two most abundant phyla in 
the gut microbiota and therefore a change within this phylum can have profound effects on 
intestinal homeostasis.  In fact, decreases in Firmicutes have been reported in inflammatory 
bowel disease and CRC [90, 92-95].  The anti-cancer effects of Firmicutes are likely due, 
at least in part, to the production of short chain fatty acids, specifically butyrate, which has 
documented effects on CRC.  Within this phylum, Lactobacillaceae represent the known 
probiotic Lactobacillus, and Clostridiaceae contain strong butyrate producers in the 
clusters IV and XIVa.  These bacteria were significantly increased in the clodronate treated 
group.  Despite differences in relative abundance within phyla and families, there were no 
significant differences between alpha or beta diversity, as shown through Chao1 index and 
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weighted UniFrac PCA plots, respectively.  This indicates that overall alpha and beta 
diversity within stool was unaffected by clodronate treatment.  Thus, our data suggest that 
macrophages may be facilitating the change in Firmicutes abundance.  However, these 
findings should be interpreted with caution as it is unclear whether the change in Firmicutes 
is a direct result of macrophage depletion or an indirect effect of the decrease in 
tumorigenesis.  Contributions from both explanations are also a possibility.  Nonetheless, 
we show a strong association between lower frequency of macrophages, increased 
Firmicutes, and decreased tumorigenesis in this model.  Together, this supports further 
evaluation of macrophage-microbiota interactions in CRC.   
In summary, we found that clodronate administration during late-stage 
tumorigenesis is effective at reducing tumor growth.  This was associated with a decrease 
in select M1 and M2 macrophage markers and chemokines in the colon tissue and a 
decrease in transcription factors that are linked to CRC.  Additionally, the clodronate-
treated group was found to have an increased abundance of Firmicutes, a phylum with 
documented anti-tumorigenic effects.  Overall, these data support the development of 
therapeutic strategies to target macrophages in CRC and provide further support for further 
evaluation of immune-microbiota interactions in CRC.   
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2.6 FIGURES & LEGENDS 
 
 
Figure 2.1: Effects of late stage clodronate administration on morphometric characteristics 
following azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment. The dashed 
line represents the initiation of clodronate treatment at week 6.5 and twice weekly i.p. 
injections for the duration of the study. A: Mouse body weight measurements through 
AOM/DSS protocol and clodronate treatments. B: Symptom score (body weight loss + 
blood in stool + diarrhea). C: Measured weekly food consumption represented as grams of 
food per mouse in cage per day. D and E: Body Composition measure via Dual-Energy X-
ray Absorptiometry (DEXA) for lean mass, fat mass and fat %. Values are means ± SE; 
n=16 mice per group. *P < 0.05. ^P < 0.10 unpaired student t-test.  
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Figure 2.2: Effect of clodronate administration on colon polyps and dysplasia. A and B: 
Polyp count and size after AOM/DSS treatment. C: Representative hematoxylin-eosin 
stained sections of distal colon tumor exhibiting high grade dysplasia after AOM/DSS 
treatment (10X magnification with 20X in upper right box, indicating that dysplastic cells 
are limited to the mucosa and do not penetrate through the muscularis mucosa). D: 
Histology evaluation of distal colon tumors (quantitatively represented as low grade 
dysplasia (1) or high grade dysplasia (2) n=4-8 colons) E: Ratio of spleen weight (mg)/ 
mouse body weight (g) following AOM/DSS treatment. F: Colon weight (after feces 
removed). G: Colon length to width ratio. Values are means ± SE; n=16 mice per group 
unless indicated. *P < 0.05. unpaired student t-test.  
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Figure 2.3: Effect of clodronate administration on gene expression in colon and colon polyp 
tissue. A-C: Quantitative RT-PCR assessment of gene expression in colon and colon tumor 
tissue. Ct values relative to 18s rRNA internal control and normalized to vehicle control 
group. Values are means ± SE; n=9 mice per group for colon tissue and n=7 mice per group 
for colon polyp tissue. *P < 0.05. unpaired student t-test.  
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Figure 2.4: Effect of clodronate administration on protein expression in colon tissue.  A: 
Western blot and corresponding amido black membrane stain of colon tissue.  B: 
Quantitative intensity of densitometry relative to total protein normalized to vehicle 
control.  Ratio= total/phosphorylated.  Values are means ± SE; n=9 mice per group.  *P < 
0.05. unpaired student t-test.  
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Figure 2.5: Effects of clodronate administration on microbiota composition in stool.  A: 
Relative abundance of OTU in bacterial Phylum following AOM/DSS treatment.  B: 
Composition of Families within the Firmicutes phylum (families with abundance less than 
0.001 are not shown).  C: Rarefraction curve within-sample Chao1 (Alpha Diversity).  D: 
Principal Coordinates Analysis plot of (Beta Diversity) distance between samples matrix.  
Text in bold indicate significant difference.  *p <0.05. n= 10 mice per group.  
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CHAPTER 3 
 
REPEATED CLODRONATE-LIPOSOME TREATMENT RESULTS IN 
NEUTROPHILIA AND IS NOT EFFECTIVE IN LIMITING OBESITY-
LINKED METABOLIC IMPAIRMENTS2 
 
 
 
 
 
 
 
 
2Bader JE, Enos RT, Velázquez KT, Carson MS, Sougiannis AT, McGuinness OP, 
Robinson CM, Murphy EA. Repeated clodronate-liposome treatment results in 
neutrophilia and is not effective in limiting obesity-linked metabolic impairments. Am J 
Physiol Endocrinol Metab. 2019 Mar 1;316(3):E358-E372 
 Reprinted here with permission from publisher 
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3.1 ABSTRACT 
Objective: Depletion of macrophages is thought to be a therapeutic option for 
obesity-induced inflammation and metabolic dysfunction.  However, whether the 
therapeutic effect is a direct result of reduced macrophage-derived inflammation or 
secondary to decreases in fat mass is controversial as macrophage depletion has been 
shown to disrupt energy homeostasis.  This study was designed to determine if macrophage 
depletion via clodronate-liposome (CLD) treatment could serve as an effective intervention 
to reduce obesity-driven inflammatory and metabolic impairments independent of changes 
in energy intake.   
Methods: Following 16 weeks of high-fat diet (HFD) or AIN-76A control diet 
(LFD) (n=30/diet treatment), male C57BL/6J mice were assigned to either a CLD or PBS-
liposome-treatment (n=15/group) for 4 weeks.  Liposomes were administered bi-weekly 
via intraperitoneal injections (8 administrations in total).  PBS-liposome-treated groups 
were pair-fed to their CLD-treated dietary counterparts.  Metabolic function was assessed 
pre- and post- liposome treatment.  Adipose tissue as well as liver were investigated for 
macrophage infiltration and the presence of inflammatory mediators.  Additionally, a 
complete blood count was performed.   
Results:  CLD treatment reduced energy intake.   When controlling for energy 
intake, CLD treatment was unable to regress metabolic dysfunction or Non-Alcoholic-
Fatty-Liver Disease, and impaired adipose tissue insulin action.  Moreover, repeated CLD 
treatment induced neutrophilia, anemia, increased adipose tissue mRNA expression of the 
pro-inflammatory cytokines, IL-6 and IL-1β, and augmented circulating IL-6 and MCP-1 
concentrations (p<0.05).  
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Conclusion: This study suggests that the repeated administration of CLD treatment 
to deplete macrophages attenuates obesity by limiting energy intake.  Moreover, after 
controlling for the benefits of weight loss, the accompanying detrimental side effects limit 
regular CLD treatment as an effective therapeutic strategy 
 
3.2 INTRODUCTION 
Obesity has been established as a public health concern given the condition’s link 
to increased health care costs, morbidity, and mortality [96].  The underlying cause of 
obesity is rooted in a lack of physical activity and an excessive intake of energy-dense 
foods resulting in the obese phenotype.  This phenotype is largely defined by two primary 
characteristics: chronic, low-grade inflammation and metabolic dysfunction.  Although it 
has been established that these two processes are linked, the degree to which one process 
regulates the other is still not completely understood.  It is believed that a main driving 
force behind the development of type 2 diabetes and insulin resistance is inflammation 
[36].  Thus, therapies designed at combating obesity-associated inflammation may protect 
against the obesity-associated metabolic diseases.   
Many different factors are thought to play a role in obesity-associated inflammation 
including, but not limited to, changes in the gut microbiota, the gut-brain axis, and non-
alcoholic-fatty-liver-disease (NAFLD) [97, 98].  However, the immune cells primarily 
responsible for adipose tissue inflammation are infiltrating pro-inflammatory 
macrophages, otherwise classified as M1 macrophages [37].  Under obese conditions, 
macrophages, predominately of the M1 phenotype, may account for approximately 50% of 
all adipose tissue cells [37].  This is in stark contrast to the lean condition, in which 
macrophages only account for approximately 10% of all adipose tissue cells, with the anti-
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inflammatory, M2 macrophage phenotype being the most predominant.  In addition to 
clearing dead adipocytes, M1 macrophages secrete a variety of pro-inflammatory 
cytokines, including TNF-α, a cytokine known to negatively impact insulin signaling [39].  
As such, depletion of macrophages to reduce macrophage-derived adipose tissue 
inflammation has been investigated as a potential therapeutic.  Depletion of macrophages 
in an obese setting reduces adipose tissue inflammation and improves insulin sensitivity 
[99, 100].  Macrophage depletion has also been shown to reduce energy intake [101] and 
body weight [101-104], and it is well known that energy restriction can attenuate 
inflammation and improve metabolic function [105-108].  Whether the beneficial impact 
of macrophage depletion extends beyond weight loss has not been examined.  
Therefore, through the utilization of pair-feeding, our study was designed to 
determine if macrophage depletion could serve as an effective intervention to reduce 
obesity-driven adipose tissue inflammation and improve metabolic dysfunction beyond the 
weight loss seen with reduced energy intake. 
 
3.3 METHODS 
Animals: Male WT C57BL/6J mice were purchased from the Jackson Laboratories 
(Bar Harbor, ME) and cared for at the Animal Resources Facility at the University of South 
Carolina.  Mice (n=15/group) were housed 5 per cage, maintained on a 12:12-h light-dark 
cycle in a low stress environment (22°C, 50% humidity, low noise) and given water ad 
libitum.  Principles of laboratory animal care were followed, and the Institutional Animal 
Care and Usage Committee of the University of South Carolina approved all experiments.  
Diets: At 6 weeks of age, mice were randomly assigned to either control purified 
AIN-76A low-fat diet (LFD) (3.77 kcal/g) or a purified HFD (40% of total kcals from fat; 
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4.57 kcal/g) designed to mimic the standard American diet (BioServ, Frenchtown, NJ, 
USA).  We have used this diet in several of our previous investigations [67, 109-113].  
Mice were initially provided the respective LFD or HFD for 16 weeks at which time 
baseline body composition (DEXA) and metabolic tests were administered.  Based upon 
these outcomes, mice within each diet were separated into one of four treatment groups 
(LFD phosphate-buffered saline (PBS)-encapsulated liposomes, HFD PBS-encapsulated 
liposomes, LFD clodronate (CLD)-encapsulated liposomes, and HFD CLD-encapsulated 
liposomes) to match body weight and composition within each dietary treatment.  
Subsequently, mice continued their respective diets (LFD or HFD) for another 4 weeks.  
Thus, in total, mice consumed diets for 20 weeks.   
Clodronate treatment & pair feeding: To deplete adipose tissue macrophages, a 
200 μl IP injection (~1mg) of CLD-encapsulated liposomes (ClodronateLiposomes, 
Netherlands) was administered twice a week beginning at week 16 of dietary treatment (8 
injections in total) until sacrifice at week 20.  The selection of this dose of CLD utilized 
was based upon pilot work that we conducted.  IP administration of CLD liposomes was 
chosen as this has previously been shown to be a more effective means of depleting adipose 
tissue macrophages compared to intravenous (IV) administration [114].  We had initially 
used the manufacturer’s recommended dose of 0.05 mg/g body weight.  However, the dose 
was scaled down to ≈0.03 mg/g body weight in an attempt to lessen toxicity, but still elicit 
significant macrophage depletion as we have previously shown with respect to colonic 
macrophages [49].  Administration of CLD treatment was initiated after 16 weeks of HFD-
feeding, as we have previously shown this length of feeding induces an obese phenotype 
characterized by adipose tissue inflammation with significant adipose tissue macrophage 
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recruitment and metabolic dysfunction [67, 109].  PBS-encapsulated liposomes 
(ClodronateLiposomes, Netherlands) were administered in the same manner as CLD 
liposomes to serve as a control.  The sample size in the LFD CLD and HFD CLD groups 
was reduced to 9 and 14 mice, respectively, due to apparent toxicity of CLD treatment.  In 
our unpublished and published [49] experiments, we have found that macrophage depletion 
reduces energy intake.  This is in accordance with another published paper, which showed 
that macrophage depletion (via the use of the diphtheria toxin) resulted in a significant 
reduction in energy intake [101].  Given this, PBS treated mice were pair-fed to their CLD-
treated counterparts so as not to allow energy intake to be a potential confounding factor 
on the outcomes of the study.  As the number of mice in each cage was equal across 
treatment groups, pair feeding calculations were determined by measuring the food 
consumption of CLD-treated animals by averaging the food intake/cage each day prior to 
administering food to the counterpart PBS-treated groups.  For example, if the 3 CLD HFD 
cages consumed 15, 16, and 16.4 grams of food over a 24-hour period, the average of this 
food consumption (=15.8 grams) was provided to each of the 3 PBS HFD cages. 
Body weights, energy intake, and body composition: Body weight was monitored 
on a weekly basis throughout the study.  Energy intake was monitored on a weekly basis 
prior to CLD treatment and on a daily basis upon the commencement of CLD treatment for 
pair-feeding purposes.  Energy intake was calculated by dividing the total food 
consumption in grams/cage/week/mouse multiplied by the energy density/gram of the 
respective diet.  Body composition was assessed before and after CLD treatments (weeks 
16 and 20).  For this procedure, mice were placed under brief anesthesia (isoflurane 
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inhalation) and were assessed for lean mass, fat mass, and body fat percentage via dual-
energy X-ray absorptiometry (DEXA) (Lunar PIXImus, Madison, WI).  
Metabolism: Metabolic parameters were assessed pre (16 weeks of dietary 
treatment) and post CLD treatment (20 weeks of dietary treatment/4 weeks of CLD 
treatment).  After a five-hour fast, blood samples were collected from the tip of the 
tail.  Blood glucose concentrations were determined in whole blood using a glucometer 
(Bayer Contour, Michawaka, IN).  Collected blood was centrifuged at 4,000 rpm for 10 
min at 4°C.  Plasma was aliquoted and stored at -80°C until analysis.  Plasma insulin 
concentrations were analyzed according to the manufacturer’s instructions using a mouse 
insulin ELISA kit (Mercodia Inc., Winston Salem, NC).  For glucose tolerance tests 
(GTTs) and insulin tolerance tests (ITTs), mice were fasted for 5 hours and glucose or 
insulin was administered (IP) at a dose of 2 g/kg or 0.75 U/kg lean mass, respectively.  
Blood glucose concentrations (tail sampling) were measured intermittently over a two hour 
period (0, 15, 30, 60, 90, and 120 minutes) for GTTs and intermittently over a one-hour 
period (0, 15, 30, 45, and 60 minutes) for ITTs using a glucometer (Bayer Contour, 
Michawaka, IN).  Area under the curve (AUC) was calculated using the trapezoidal rule.  
Fasting serum was collected for free-fatty acid (FFA) analysis at the 0- and 30-minute time 
point of the post-CLD treatment ITT to assess insulin’s ability to inhibit lipolysis.  FFAs 
were analyzed using a commercially available kit according to the manufacturer’s 
instructions (Wako Diagnostics, Richmond, VA).   
Tissue collection: After 20 weeks of dietary treatment (4 weeks after CLD treatment), mice 
were sacrificed via isoflurane inhalation for tissue collection.  An aliquot of whole blood 
taken from the inferior vena cava was analyzed for hematology analysis using a VetScan 
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Hm5 (Abaxis, Union City, CA).  The remaining blood was spun at 4,000 RPM x 10 min 
and plasma was stored -80°C.  Epididymal, mesentery, and peri-renal fat pads, as well as 
the liver were removed, weighed, and immediately snap-frozen in liquid nitrogen and 
stored at −80°C or fixed in 4% formalin until analysis. 
Hepatic lipid content and alanine transaminase activity (ALT) assay: Lipids were 
isolated from the liver utilizing a modified Folch extraction method and were quantified 
gravimetrically, as previously described [109, 111, 112, 115, 116].  Plasma ALT activity 
was assessed using an Infinity ALT liquid reagent (Thermo Fisher, Middletown, VA) 
following the manufacturer’s instructions.   
Adipose tissue hydroxyproline assessment: In order to assess the impact of 
macrophage depletion on adipose tissue fibrosis, epididymal adipose tissue hydroxyproline 
content (an indirect method for assessing collagen deposition[117]) was examined.  Due to 
limitations in the amount of available epididymal adipose tissue, this assay was limited to 
the adipose tissue of HFD groups only.  Briefly, 100-200 mg of epididymal adipose tissue 
was acid hydrolyzed overnight at 110ºC using 6N HCL.  The solution was then centrifuged 
(10 min x 10,000 RPM) and the resulting supernatant was collected and dried under 
nitrogen gas.  Subsequently, the dried extract was incubated with 0.625 mLs of a 
chloramine-T solution for a 30 minute period followed by the addition of 0.625 mLs of 
Ehrlich’s solution as previously described [118].  Samples were then incubated for 20 min 
at 65ºC, cooled in room temperature water, and then transferred to a 96-well microplate 
and read using a spectrophotometer at 550 nm.  Hydroxyproline purchased from Sigma 
Aldrich (St. Louis, MO) was used to create a standard curve.  Total hydroxyproline content 
was normalized to the epididymal adipose tissue weight originally used.   
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Adipose Tissue and Liver Histology: Formalin-fixed tissues were embedded in 
Paraffin blocks and sectioned.  The epididymal and peri-renal fat pads and livers were 
stained with H&E.  Representative images were taken at 20x and 100x.  For 
immunofluorescent and immunohistochemistry staining, the antibodies, antibody 
dilutions, and antigen-retrieval methods are provided in Table 1.  For negative controls, a 
serial section was assayed exactly the same as the treated-section minus the primary 
antibody.     
Quantitative real-time RT-PCR:  RNA was isolated from epidydimal and peri-renal 
adipose tissue depots as well as liver using an RNeasy Lipid Tissue Mini Kit (Qiagen, 
Valencia, CA).  TaqMan reverse transcription reagents and gene expression assays 
(Applied Biosystems, Foster City, CA) were used to reverse transcribe and to analyze the 
expression of the following genes: F4/80, CD68, CD11c, CD206, MCP-1, TNFα, IL-10, 
IL-6, and IL-1β.  Potential reference genes (RPLP2, 18s, HMBS, TBP, B2M, H2AFV, and 
HPRT) were analyzed for stability using Qbase+ software (Biogazelle, Belgium) for each 
tissue analyzed.  The optimal number of reference genes were determined by Qbase+ and 
the geometric mean of these genes was used as the normalization factor for each analysis: 
epididymal adipose tissue (HMBS, TBP, B2M, and H2AFV), peri-renal adipose tissue 
(HMBS and HPRT), and liver (TBS and B2M) [119].  Gene expression quantification was 
calculated using the ΔΔCT method and Qbase+ software.  
Western Blotting: Briefly, epididymal and peri-renal adipose tissue, as well as a 
portion of the liver was homogenized in Mueller Buffer containing a cocktail protease 
inhibitor (Sigma Aldrich, St. Louis, MO) [70].  Total protein concentrations were 
determined by the Bradford method.  Equal amounts of crude protein homogenates were 
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fractioned on hand-casted 12% SDS-polyacrylamide gel and electrophoretically 
transferred to a PVDF membrane using a Genie Blotter (IDEA Scientific, Minneapolis, 
MN).  Membranes were stained with a Ponceau S solution in order to verify equal protein 
loading and transfer efficiency.  Subsequently, membranes were blocked for 1 hour in 5% 
milk in Tris-buffered saline, 0.1% Tween-20 (TBST).  The Ly6G primary antibody 
(Abcam, Cambridge, UK) was diluted 1:1,000 in a 5% milk-TBST overnight at 4ºC.  An 
anti-rat (Cell Signaling, Danvers, MA) IgG horseradish peroxidase conjugated secondary 
antibody was diluted 1:2000 in 5% milk-TBST and incubated for 1 hour at room 
temperature.  An enhanced chemiluminescent substrate for detection of horseradish 
peroxidase (Thermo Scientific, Watham, MA) was used to visualize the antibody-antigen 
interaction.  Autoradiography films were scanned and blots were quantified using scientific 
imaging software (Image J).  Due to tissue limitations, only the peri-renal fat from HFD-
fed animals was analyzed for Ly6G content.  After completion of the western blot, all 
membranes were stained with Amido black [49, 109, 116], and the densitometry of each 
lane was calculated using Quantity One Software (Biorad, Hercules, CA) allowing for total 
protein normalization.  This method of normalization has been shown to be more accurate 
than typically used loading controls [71].    
Plasma Cytokines: Plasma collected at sacrifice was analyzed for circulating IL-6 
and MCP-1 (LEGEND MAX ELISA kits, Biolegend, San Diego, CA).  Due to limitations 
in the amount of plasma only the plasma of the HFD-treated groups was analyzed for MCP-
1 concentration. 
Statistical Analysis: Data were analyzed using commercially available statistical 
software: Prism 6 (GraphPad Software, La Jolla, CA)) and SigmaStat (Systat Software, 
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San Jose, CA).  A two-way ANOVA followed by a Newman-Keuls post-hoc analysis was 
used to determine differences between diet (HFD vs. LFD) and treatment (CLD vs. PBS).  
For body weight analysis a two-way (time x group) repeated measures ANOVA was used 
followed by a Newman-Keuls post-hoc test.  A two-way (time x group) repeated measures 
ANOVA followed by a Newman-Keuls post-hoc test was also used for ITT analysis in 
order to determine differences in blood glucose levels from baseline (0 minutes) over the 
duration of the test.  A Student’s T-Test (two-tailed) was used for western blot analysis of 
Ly6G, epididymal adipose tissue hydroxyproline content, and plasma MCP-1 
concentrations to compare treatment (CLD vs. PBS) within diet.  Statistical analysis of 
energy intake was not assessed given the small sample size (n=3/group).  Any statistical 
test that did not pass the equal-variance test (Bartlett’s test for equal variances) was log 
transformed and then re-analyzed.  Data are presented as the mean ± SEMs and the level 
of significance was set at p<0.05.   
 
3.4 RESULTS 
16 weeks of HFD consumption leads to an obese phenotype 
 Prior to CLD or PBS treatment, mice were fed a 40% HFD or a LFD for 16 weeks.  
An obese phenotype was successfully achieved as the HFD-fed mice gained significantly 
more body weight, fat mass, and displayed a significantly greater body fat % (Figure 3.1A-
B) compared to LFD fed mice (p<0.05).  HFD-fed mice also displayed elevated fasting 
blood glucose, insulin, GTT AUC, and impaired insulin sensitivity (Figures 3.1C, 1D, 1E, 
and 1G, respectively), demonstrating a dysfunctional metabolic phenotype (p<0.05).    
CLD treatment reduces body weight by eliciting changes in energy intake  
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 After 16 weeks of HFD or LFD consumption, mice were administered either PBS 
or CLD-encapsulated liposomes for a 4-week period.  The PBS-treated groups were pair-
fed the same amount of food as their CLD-treated counterparts.  All CLD-treated groups 
displayed a decrease in body weight starting one week after CLD treatment (Figure 3.2A) 
which was accompanied by a decrease in energy intake (Figure 3.2B) suggesting that CLD 
treatment induced a reduction in appetite.  There was a main effect of the HFD-treatment 
to increase lean mass, fat mass, and body fat% relative to the LFD-fed mice (Figure 3.2C) 
(p<0.05).  Pair feeding was successful in matching the body weight, fat mass and lean mass 
in the PBS and CLD treatment groups.   However, within the LFD groups, CLD treatment 
significantly reduced body fat% (Figure 3.2C) (p<0.05).  With respect to intra-peritoneal 
fat pads, HFD increased all fat pad weights (epididymal, mesentery, and peri-renal) relative 
to the LFD-fed mice (Figure 3.2D) (p<0.05).  Interestingly, within the HFD-treated mice, 
CLD-treated mice exhibited an increase in epididymal, but not peri-renal or mesenteric, fat 
pad weight.  Consequently, the sum of all three fat pads was also increased (Figure 3.2D) 
(p<0.05).  We found this surprising, and in order to potentially explain this discrepancy, 
we examined a marker of extracellular matrix (Collagen) accumulation, hydroxyproline 
content, in epididymal adipose tissue (HFD groups only).  However, no significant 
difference was found in hydroxyproline content (data not shown) between these groups, 
suggesting that some other mechanisms are responsible for the expansion of epididymal 
fat pad weight between the HFD groups.    
CLD-liposome treatment does not reduce epididymal adipose tissue macrophage 
populations in a HFD setting, yet results in an exacerbated cytokine profile, and significant 
increases in circulating and infiltrating neutrophils   
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 We initially examined epididymal adipose tissue to assess the effectiveness of CLD 
treatment to deplete macrophages as the epididymal fat pad has been shown to develop 
signs of inflammation and insulin resistance prior to other intraperitoneal fat pads [120].  
Interestingly, while as expected, the HFD increased adipose tissue macrophage markers, 
no significant difference was found with respect to gene expression of overall macrophage 
markers, F4/80 and CD68, or M1 (CD11c) and M2 (CD206) macrophage markers between 
the HFD groups (Figure 3.3A).  This lack of difference in macrophage populations was 
substantiated when we performed immunofluorescence staining in the epididymal fat pad 
(Figure 3.3B).  However, within the LFD groups, CLD treatment significantly decreased 
F4/80 (-58%), CD68 (-52%), and CD206 (-72%) gene expression, but not CD11c mRNA 
expression (Figure 3.3A) (p<0.05).   
 We then proceeded to examine the gene expression of various inflammatory 
cytokines in the epididymal fat pad (Figure 3.4A) (p<0.05).  As expected, HFD treatment 
significantly increased the gene expression of the monocyte chemoattractant, MCP-1, the 
pro-inflammatory cytokine, TNF-α, as well as the anti-inflammatory cytokine, IL-10, 
relative to the LFD groups (p<0.05).  However, within the HFD groups, CLD treatment 
further elevated gene expression of MCP-1 and IL-10 (p<0.05).  An additional interest was 
the finding that CLD treatment, independent of diet, resulted in substantial increases in 
mRNA expression of the pro-inflammatory cytokines, IL-6 and IL-1β (p<0.05).  In fact, 
IL-1β mRNA induction was further augmented in the CLD LFD group relative to the CLD 
HFD group, whereas its expression was downregulated in the HFD PBS group relative to 
the LFD PBS group (p<0.05).   
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Based on these findings, we performed H&E staining to histologically assess the 
epididymal fat pads (Figure 3.4B).  We found clear evidence of infiltrating 
polymorphonuclear cells (PMCs) in the CLD-treated groups relative to the PBS-treated 
groups.  Additionally, in whole blood collected at sacrifice, we found significant increases 
in circulating neutrophils in the CLD-treated groups (Figure 3.5A).  This finding led us to 
believe that the tissue PMCs we examined histologically, were neutrophils.  As such, we 
performed a western blot for Ly6G, a neutrophil marker, and found significant increases in 
Ly6G in the CLD-treated groups relative to their PBS controls (Figure 3.5B) (p<0.05).  
This discovery was corroborated with immunohistochemistry staining of Ly6G (Figure 
3.5C).   
Macrophage populations are significantly diminished in peri-renal adipose tissue, yet a 
pro-inflammatory environment including neutrophil infiltration is evident 
 Because we did not find any significant decreases in macrophage populations in the 
epididymal fat pad, we decided to assess the peri-renal fat pad with respect to macrophage 
infiltration.  Contrary to the finding in the epididymal fat pad, CLD treatment significantly 
decreased F4/80 (-30%), CD68 (-35%), CD11c (-40%), and CD206 (-42%) in the CLD 
HFD group relative to the PBS HFD group (Figure 3.6A) (p<0.05), which was corroborated 
with immunofluorescent staining for F4/80 (Figure 3.6B).  In the LFD groups, a similar 
pattern was found as CLD treatment reduced mRNA content of F4/80 (-43%), CD68 (-
35%), and CD206 (-47%) (Figure 3.6A) (p<0.05).  However, similar to the epididymal 
adipose tissue, CLD treatment did not influence CD11c gene expression.    
 Since we found reduced macrophage populations in the CLD-treated groups, we 
moved on to explore the gene expression of several pro-inflammatory cytokines (TNF-α, 
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MCP-1, IL-1β, and IL-6).  As expected, there was a HFD effect to increase TNF-α and 
MCP-1 expression (Figure 3.7A) (p<0.05).  On the other hand, IL-6, similar to the finding 
in epididymal adipose tissue, was downregulated as a result of HFD consumption (p<0.05).  
In a HFD setting, CLD treatment significantly decreased TNF-α gene expression (-31%), 
which corresponded with the similar decrease (-30%) in F4/80 mRNA (Figure 3.7A) 
(p<0.05).  However, analogous to what was observed in the epididymal adipose tissue, 
MCP-1, IL-1β, and IL-6 were all increased as a result of CLD treatment among the HFD 
groups (Figure 3.7A) (p<0.05).  A similar finding was observed with CLD treatment in a 
LFD setting as both IL-1β and IL-6 expression were significantly increased (p<0.05).  This 
outcome, paired with no change in MCP-1 gene expression, paralleled what was observed 
in epididymal adipose tissue. 
 We followed up the qRT-PCR analysis with a histological assessment of the peri-
renal fat pad and, similar to what was observed in the epididymal fat pad, discovered an 
abundance of infiltrating PMCs surrounding adipocytes.  Immunohistochemistry 
confirmed that these cells were Ly6G positive cells (Figure 3.7B).  A western blot analysis 
of Ly6G verified that Ly6G content was greater in the CLD-treated mice (Figure 3.7C) 
(p<0.05). 
CLD treatment does not regress early-stage NAFLD development   
 HFD treatment resulted in early-stage NAFLD development as characterized by 
hepatomegaly (Figure 3.8A), hepatic steatosis (Figure 3.8B & 8D), and elevated plasma 
ALT activity (Figure 3.8C) (p<0.05).  However, the disease had not progressed to 
steatohepatitis as the HFD PBS group, although it did display an increase in F4/80 
expression relative to the LFD PBS group (Figure 3.8E & 8F) (p<0.05), did not 
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histologically present significant evidence of immune cell infiltration.  Moreover, nor were 
there any significant increases in any of the pro-inflammatory cytokines measured, 
including MCP-1, TNF-α, IL-6, and IL-1β (Figure 3.8G).  In fact, there was a main effect 
for HFD consumption to decrease MCP-1 gene expression, and the HFD PBS group 
displayed less TNF-α gene expression relative to the LFD PBS group (p<0.05). 
Regardless of the lack of HFD-induced hepatic inflammation, CLD treatment 
significantly reduced gene expression of F4/80 (-59%) in a HFD setting (Figure 3.8E).  
This was substantiated by F4/80 staining (Figure 3.8F) and occurred independent of any 
changes to liver weight or hepatic lipid accumulation.  Surprisingly, this decrease in F4/80 
did not impact gene expression of MCP-1 or TNF-α (Figure 3.8G).  Additionally, CLD 
treatment in a LFD setting did not significantly reduce macrophages as substantiated by 
F4/80 gene expression and immunohistochemistry (Figures 8E & 8F, respectively), yet 
there was a main effect for CLD treatment to decrease TNF-α and IL-1β (Figure 3.8G) 
(p<0.05).  Despite these reductions in TNF-α and IL-1β, CLD treatment, independent of 
diet, resulted in higher IL-6 gene expression (Figure 3.8G) (p<0.05).      
Macrophage depletion elicits significant increases in circulating IL-6 and MCP-1 
 Because we found a main effect of CLD treatment to increase gene expression of 
IL-6 in all tissues analyzed and an interaction for CLD treatment to increase epididymal 
and peri-renal MCP-1 gene expression among the HFD groups, we examined circulating 
IL-6 and MCP-1 levels (Figure 3.9).  Consistent with the gene expression, CLD treatment, 
irrespective of diet, induced significant increases in the plasma IL-6 concentration (Figure 
3.9A) (p<0.05).  Additionally, CLD-treated HFD mice displayed >2-fold increases in 
circulating MCP-1 relative to HFD PBS mice (Figure 3.9B) (p<0.05).   
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Macrophage depletion does not rescue impaired glucose metabolism or insulin resistance 
and exacerbates adipose tissue insulin action 
 CLD treatment had no effect at improving glucose metabolism or insulin resistance 
as fasting blood glucose (Figure 3.10A), fasting insulin (Figure 3.10B), and GTT AUC 
(Figure 3.10C), were not reduced with CLD treatment in either the LFD or HFD groups.  
Similarly, insulin’s ability to decrease blood glucose levels (Figure 3.10D) was not 
enhanced with CLD treatment in either the LFD or HFD setting.  With respect to FFA 
metabolism, basal serum FFAs were significantly increased in the LFD PBS group 
compared to all other groups (Figure 3.10E) (p<0.05).  Thirty minutes after exogenous 
insulin administration there was a main effect of diet (p<0.05) for the LFD-fed mice to 
exhibit significantly lower serum FFAs than HFD-fed mice (Figure 3.10F).  When 
examining the absolute change of serum FFAs over the thirty-minute period, there was a 
main effect of CLD treatment to impair the decrease in serum FFAs compared to PBS 
treatment.  Among the groups, the LFD PBS group displayed the greatest drop in serum 
FFAs compared to all other groups (Figure 3.10G) (p<0.05).  LFD CLD mice exhibited a 
more significant drop in serum FFAs than the HFD CLD mice (p<0.05), but not when 
compared to the HFD PBS mice.  Although not statistically significant, there was a trend 
(p=0.08) for the HFD PBS mice to decrease serum FFAs more so than the HFD CLD group.   
CLD treatment results in anemia 
 It is well established that macrophages play a central role in heme-iron metabolism 
[121-123].  Therefore, we analyzed whole blood to see if CLD treatment impacted 
hemoglobin levels.  Data from the hematology analysis showed that CLD treatment, 
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independent of diet, decreased absolute hemoglobin levels and the hematocrit (Table 3.2) 
(p<0.05).   
 
3.5 DISCUSSION 
  Due to the prominent role macrophages play in obesity-associated inflammation, 
they have become the target for therapies aimed at mitigating the chronic inflammatory 
environment and impaired metabolic processes.  As others have reported, adipose tissue 
macrophages (peri-renal) were successfully reduced with CLD-liposome treatment [99, 
100, 114, 124].  However, relative to weight-matched control animals, CLD treatment did 
not rescue HFD-induced impaired glucose metabolism.  Moreover, CLD treatment, 
irrespective of diet, increased circulating and adipose tissue infiltrating neutrophils.  
Additionally, we found that CLD treatment resulted in reduced energy intake and 
significant body weight loss.   
Interestingly, others who have utilized CLD liposomes to decrease obesity-induced 
adipose tissue macrophage infiltration have not reported similar findings of neutrophilia, 
an inability to rescue impaired metabolism, and reduced energy intake [99, 100, 104, 124].  
However, our results are consistent with those of Lee et. al., who found that macrophage 
depletion utilizing a Lysozyme M promoter-directed CRE (LysMCre) diphtheria toxin 
model resulted in significant neutrophil infiltration, decreased energy intake, and reduced 
body weight in both HFD and standard-chow-fed mice [101].  Similarly, Gordy et. al. 
developed a LysMCre floxed FLICE-like inhibitory protein (LysMCre c-FLIPf/f) mouse 
model which results in mice lacking splenic marginal zone, bone marrow, and 
thioglycolate-elicited peritoneal macrophages and found that neutrophilia is secondary to 
macrophage depletion and macrophages regulate neutrophil homeostasis [102].   Although 
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energy intake was not measured in the study by Gordy et. al., it was discovered that these 
mice exhibit a decreased body weight.  Similar results of neutrophilia and a loss of body 
weight were reported by Wu et. al. when conditional macrophage depletion via the use of 
a transgenic mouse model was used to study the impact of macrophages on osteoarthritis 
in obesity [103].  The results of Lee et. al., Gordy et. al., and Wu et. al. and the mouse 
models utilized in their studies provide support that our findings are a direct result of 
macrophage depletion and not of CLD liposome treatment alone.   
 It was surprising that we did not find significant decreases in macrophage 
populations in the epididymal adipose tissue of the HFD CLD group.  It was our initial 
hypothesis that epididymal adipose tissue would be the most sensitive to CLD treatment 
given the route of liposome administration and that the epididymal fat pad exhibits 
exacerbated inflammation and impaired insulin action at an earlier time point than other 
intra-peritoneal fat pads [120].  However, the fact that CLD treatment significantly 
depleted epididymal and peri-renal adipose tissue macrophages in a LFD setting and 
resulted in significant peri-renal adipose tissue macrophage depletion in a HFD setting 
leads us to believe that perhaps epididymal adipose macrophages are more sensitive to the 
pair feeding.  Prior work demonstrated that restricting food intake in obese animals reverses 
macrophage accumulation in peri-gonadal adipose tissue [125].  As we are comparing the 
CLD treatment to pair-fed animals who lost weight, it is possible that CLD could not reduce 
macrophage populations beyond that seen with caloric restriction.  Alternatively, the 
inability to detect a difference in epididymal adipose tissue macrophage populations may 
be due to the immune system’s ability to compensate for the effects of CLD treatment in 
order to recruit more monocytes to the inflamed area resulting in a repopulation of 
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macrophages.  This is supported by the significant increase in epididymal mRNA 
expression of the potent monocyte chemokine, MCP-1 (as has been previously shown with 
acute IP CLD liposome treatment [114]), a higher concentration of circulating MCP-1 as 
well as tissue neutrophilia in the HFD CLD group.  However, a time-course study with 
CLD treatment would be necessary to confirm this.       
It is important to consider that dendritic cells, another phagocytic immune cell, are 
also known to be affected by CLD-liposome treatment [126].  Thus, the neutrophil 
infiltration makes physiological sense as they are the only primary professional phagocytic 
cell remaining after macrophage and dendritic cell depletion.  Neutrophil infiltration into 
the adipose tissue serves two probable functions: 1) remove dead immune cells affected by 
CLD treatment, and 2) adopt the role of macrophages by cleaning up dead adipocytes.  This 
is supported by the observation of Ly6G positive cells surrounding adipocytes in the CLD-
treated mice.  Additionally, it is likely that the increased expression of adipose tissue IL-6 
and IL-1β as well as the circulating IL-6 concentration originates from these infiltrating 
neutrophils as the HFD PBS treatment did not induce significant increases in these 
cytokines relative to the LFD PBS group.  Furthermore, both Lee et. al. and Gordy et. al. 
found that macrophage-depletion-induced neutrophilia resulted in significant increases in 
circulating plasma cytokines, including IL-6 [101, 102] and IL-1β [102].  However, we 
cannot rule out the possibility that other immune cells, such as T-Cells, or adipocytes could 
be producing these cytokines. 
There is a clear discrepancy between the results of our study and the studies of 
others who have shown macrophage depletion to improve metabolic processes through the 
use of CLD treatment [99, 100, 104, 124, 127].  In particular, our results are in direct 
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contradiction of Lee et. al. who have suggested that “long-term” obesity-associated insulin 
resistance, as would be induced after 16 weeks of HFD consumption, is largely mediated 
by macrophage-induced pro-inflammatory actions [124].  These discrepancies may be 
explained by many factors including, but not limited to, the type of HFD utilized, the mode 
of CLD administration (IP vs. IV), as well as the dose, timing, and duration of CLD 
treatment.  For instance, the mode of CLD liposome administration can have a significant 
effect on the tissue specificity of macrophage depletion.  Lanthier et. al. showed that IV 
administration of CLD liposomes selectively depletes Kupffer cells (liver macrophages), 
whereas IP administration is more advantageous for adipose tissue macrophage depletion 
[114].   With this being said, the majority of previous studies employing CLD liposomes 
to deplete adipose tissue macrophages have utilized IP administration [99, 100, 104, 124, 
127] as was used in our experiment.  However, the CLD dose (≈0.03 mg/g body weight) 
utilized in our study was significantly less than what others have used (≈0.1 mg/g body 
weight) [99, 100, 124].  Furthermore, the degree to which the duration of CLD liposome 
treatment impacts the effectiveness of macrophage depletion and the resulting impact on 
metabolic function is conflicting.  Studies that have employed IP administration of CLD 
liposomes for a relatively short period (1-2 weeks), such as Feng et. al. [100], Choe et. al. 
[127] (2 treatments/week x 1 week) and Lee et. al. (“5 injections every 3 days for 14 days” 
(provided in supplementary data of their paper)) [124] have shown effective macrophage 
depletion and beneficial effects on metabolic outcomes.   The duration (2 treatments/week 
x 4 weeks) of CLD liposome administration in our study was significantly longer than these 
previous studies and may be largely responsible for the discrepancy in outcomes between 
studies.  However, Bu et. al. used CLD liposome treatment for a significantly longer 
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duration (2 treatments/week x 9 weeks) than what was used in our study yet showed 
beneficial effects on adiposity and metabolism [99].   
A potential confounding factor for the majority of the previous studies utilizing IP 
CLD-liposome treatment, however, is the failure to examine/report energy intake or body 
weight changes with CLD treatment [100, 124, 127].  Moreover, those studies that did 
report significant changes in body weight did not report energy intake as exemplified in a 
recent publication by Kumar et. al. who used a similar dose of CLD liposome as the dose 
utilized in our study (≈0.03 mg/g body weight administered weekly for 4 weeks) and found 
that CLD liposome treatment significantly depleted adipose tissue macrophages, improved 
metabolic outcomes, and dramatically reduced adiposity by >50% [104].  In the publication 
by Bu et. al., food intake was reported, however, the authors did not specify the number of 
mice housed/cage, the means by which energy intake was calculated if multiple mice were 
housed/cage, and the statistical analysis utilized to assess a potential difference in energy 
intake [99].  Thus, in these previous studies any potential benefits with respect to decreases 
in adiposity, inflammation, insulin resistance, and hepatic steatosis as a consequence of 
macrophage depletion, may in reality simply be a secondary effect resulting from decreased 
energy intake.   
Although it was beyond the scope of our investigation, it is likely that the reduced 
energy intake and consequential body weight loss resulting from CLD-liposome treatment 
is due to neutrophilia, an exacerbated circulating pro-inflammatory environment, and brain 
inflammation.  However, it cannot be ruled out that liposome treatment, alone, may have 
reduced food intake as previously discussed [128].  With this being said, in our previous 
publication we did not find any effect of PBS-liposome treatment to impact body weight 
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or food intake [49].  Moreover, the concept that reduced energy intake is due to CLD-
liposome treatment and subsequent macrophage depletion and not liposome treatment, in 
general, is supported by the findings of Lee et. al. who showed that macrophage-depleted 
mice present hypothalamic inflammation and reduced energy intake [101].  It has also been 
shown that IL-1β plays a key role in regulating this effect as Gordy et. al. found that 
administration of IL-1Ra to macrophage-deficient mice rescued the decreased body weight 
[102].  Consistent with this, both in the present investigation and in that of Lee et. al., 
decreased energy intake was observed with macrophage depletion as was increases in 
adipose tissue IL-1β gene expression, which Lee et. al. also found to be elevated in the 
hypothalamus [101].   
Others have shown that hepatic resident macrophage (Kupffer cells) activation has 
been shown to impair insulin signaling in the early stages of HFD consumption [129].  As 
such, we assessed whether or not CLD treatment reduced Kupffer cell accumulation in our 
model.  Although there was evidence of NAFLD, as assessed by hepatic steatosis, elevated 
plasma ALT activity, and an increased macrophage content, there was no effect of the HFD 
to induce robust hepatitis as substantiated by no significant increases in various 
inflammatory markers (MCP-1, TNF-α, IL-6, and IL-1β).  It is likely that a longer feeding 
period would be necessary to develop a more advanced NAFLD phenotype.  Nonetheless, 
CLD treatment significantly decreased macrophages (F4/80) in a HFD setting.  However, 
glucose metabolism was not improved.  Lanthier et. al. found similar results and concluded 
that Kupffer cell depletion does not provide a therapeutic effect on detrimental metabolic 
changes induced by a HFD [114].  Thus, our results provide further support that ectopic 
lipid accumulation resulting from a positive energy balance may be a more important 
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instigator if impaired metabolic processes than inflammation as has been previously shown 
[130].     
A limitation of our study is that CLD treatment is a non-specific means of depleting 
macrophage populations.  It is well established that different macrophage subsets exist, that 
are generally categorized into two extreme phenotypes – pro-inflammatory and anti-
inflammatory.  Although this dichotomy does not fully reflect the heterogeneity of 
macrophage populations, it is still a widely used distinguishing characteristic.  Therapies 
specifically targeting individual macrophage phenotypes or specific tissue macrophage 
may be more effective than general systemic macrophage depletion [131].  However, the 
establishment of such models and tissue specificity is still in its infancy.   
It is important to note that CLD-treated groups displayed symptoms of anemia.  
Macrophages play an essential role in heme and iron metabolism [121-123].  Iron can also 
modulate glucose homeostasis and adipose tissue function [132].  Thus, it is imperative 
that a complete blood count be part of a routine assessment when interventions aimed at 
modulating macrophage populations are utilized.  This is especially true in an obese setting 
as obesity is emerging as a risk factor for iron deficiency [133].  It is also evident from our 
results that severe macrophage depletion and subsequent compensatory immune responses 
can be lethal in certain conditions.  This is consistent with other macrophage-depletion 
models [134, 135].  We hypothesize that the larger degree of toxicity observed in the LFD 
CLD group is the result of an immunocompromised state from severe macrophage 
depletion not reached in the HFD CLD group.  This is likely the case given that adipose 
tissue macrophage populations of the LFD group would have been significantly less than 
the HFD-fed mice after 16 weeks of dietary treatment, as we have previously shown [67, 
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109].  Future assessments to evaluate potential toxicity of macrophage depletion - even in 
the short-term - are necessary prior to any clinical interventions aimed at macrophage 
diminution.    
In conclusion, our study shows that when controlling for energy intake, depleting 
macrophages using CLD in an obese setting is not an effective therapy for rescuing 
metabolic dysfunction and may increase the risk for anemia, neutrophilia, and exacerbated 
adipose tissue inflammation.  Thus, the utilization of pro-longed repeated IP CLD liposome 
treatment to deplete macrophages does not seem to be a viable option as a potential clinical 
therapy.  Future studies are necessary to better understand the role that the timing, tissue-
specificity, and phenotype of macrophage depletion has on obesity outcomes. 
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3.6 FIGURES & LEGENDS 
Table 3.1. Primary and secondary antibodies as well as conditions used for 
immunofluorescence and immunohistochemistry.   
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Figure 3.1.  Body composition and metabolic data after 16 weeks of dietary treatment prior 
to start of liposome treatment.  Mice were fed a high-fat diet (HFD) or (LFD) for 16 weeks.  
A) Mouse body weight, B) body composition, C) fasting (5 hour) blood glucose levels, D) 
fasting (5 hour) plasma insulin levels, E) intraperitoneal (IP) glucose tolerance test (GTT) 
and corresponding area under the curve (AUC), F) IP insulin tolerance test (ITT) following 
a 5-hour fast.  Values are means ± SE; n=9-15 mice per group.  * and bar graphs not sharing 
a common letter are significantly different from one another (p<0.05).  %, $, #, ^ represent 
statistically significant differences (p<0.05) in blood glucose levels from baseline (0 
minutes) for the LFD PBS, LFD CLD, HFD PBS, and HFD CLD groups, respectively.  
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Figure 3.2. Body morphology following dietary and liposome treatment.  A) Mouse body 
weight, B) energy (kcal) intake throughout the experimental protocol, C) terminal body 
composition analysis as assessed by DEXA, and D) intra-peritoneal adipose tissue depot 
weights (epididymal, peri-renal, mesentery) and total intra-peritoneal fat weight measured 
at sacrifice.  Values are means ± SE; n=9-15 mice per group.  *Signifies significant 
difference from start of liposome treatment at 16 weeks.  Bar graphs not sharing a common 
letter are significantly different from one another (p<0.05). 
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Figure 3.3. Four weeks of CLD treatment depletes epididymal adipose tissue macrophages 
in a low-fat diet (LFD) setting, but not under high-fat diet (HFD) conditions.  (A) 
Epididymal adipose tissue mRNA expression of macrophage markers (F4/80, CD68, 
CD11c, and CD206) normalized to the most stable internal reference genes calculated 
using Qbase+ software, and B) representative immunofluorescent images (40X) of DAPI 
and F4/80 in epididymal adipose tissue of HFD-treated mice.  Values are means ± SE; n=9-
15 mice per group.  Bar graphs not sharing a common letter are significantly different from 
one another (p<0.05).  
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Figure 3.4.  Despite not affecting epididymal adipose tissue macrophage populations in a 
HFD setting, CLD treatment augments epididymal adipose tissue inflammation and 
polymorphonuclear cell (PMC) infiltration.  A) Epididymal adipose tissue mRNA 
expression of inflammatory mediators (MCP-1, TNF-α, IL-10, IL-6, and IL-1β) 
normalized to the geometric mean of the most stable internal reference genes calculated 
using Qbase+ software, and B) representative images (20X and 100X) of H&E stained 
epididymal adipose tissue sections showing increased (PMC) infiltration in the CLD-
treated groups. Values are means ± SE; n=9-15 mice per group.  Bar graphs not sharing a 
common letter are significantly different from one another (p<0.05). 
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Figure 3.5.   CLD treatment increases circulating and epididymal adipose tissue 
neutrophils.  A) Circulating neutrophils determined in whole blood by a VetScan HM5, B) 
western blot analysis of Ly6G (neutrophil marker) in epididymal adipose tissue normalized 
to total protein stain (amido black), and C) two representative images of 
immunohistochemistry staining (100x) of Ly6G in epididymal adipose tissue.  Values are 
means ± SE; n=9-15 mice per group.  Bar graphs not sharing a common letter and the * 
represent a statistically significant difference between groups (p<0.05). 
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Figure 3.6. Four weeks of CLD treatment depletes macrophages in the peri-renal fat pad.  
A) Peri-renal adipose tissue mRNA expression of macrophage markers (F4/80, CD68, 
CD11c, and CD206) normalized to the geometric mean of the most stable internal reference 
genes using QBase+ software, and B) representative immunofluorescent images (40X) of 
DAPI and F4/80 in peri-renal adipose tissue of HFD-treated mice.  Values are means ± SE; 
n=9-15 mice per group.  Bar graphs not sharing a common letter are significantly different 
from one another (p<0.05). 
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Figure 3.7. An increase in peri-renal adipose tissue inflammation is paired with an increase 
in infiltrating neutrophils.  A) Peri-renal adipose tissue mRNA expression of inflammatory 
mediators (TNF-α, MCP-1, IL-1β, and IL-6) normalized to the geometric mean of the most 
stable internal reference genes using QBase+ software, B) two representative images of 
immunohistochemistry staining (100x) of Ly6G in peri-renal adipose tissue of HFD-treated 
groups, C) western blot analysis of Ly6G in epididymal adipose tissue normalized to total 
protein stain (amido black).  Values are means ± SE; n=9-15 mice per group.  Bar graphs 
not sharing a common letter and the * represent a statistically significant difference 
between groups (p<0.05).    
  
 
65 
 
 
Figure 3.8. CLD treatment has no affect at regressing early-stage NAFLD development.  
A) Liver weight following sacrifice, B) hepatic lipid accumulation, C) plasma Alanine 
Transaminase (ALT) Activity, D) representative hepatic H&E (20x) images, E) hepatic 
gene expression of F4/80, F) representative F4/80 staining (60x, arrows indicate examples 
of positive staining), and G) mRNA expression of hepatic inflammatory mediators (MCP-
1, TNF-α, IL-6, and IL-1β) normalized to the geometric mean of the most stable internal 
reference genes using QBase+ software. Values are means ± SE; n=9-15 mice per group.  
Bar graphs not sharing a common letter are significantly different from one another 
(p<0.05).  %, $, #, ̂  represent statistically significant differences (p<0.05) in blood glucose 
levels from baseline (0 minutes) for the LFD PBS, LFD CLD, HFD PBS, and HFD CLD 
groups, respectively. 
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Figure 3.9.  CLD treatment significantly increases circulating pro-inflammatory cytokine 
concentrations.  After 20 weeks of diet/4 weeks of clodronate liposome treatment, plasma 
was assessed for circulating pro-inflammatory cytokines: A) IL-6 and (B) MCP-1.  Due to 
limitations in the amount of plasma, only the plasma of HFD-treated groups was assessed 
for the concentration of circulating MCP-1.  Values are means ± SE; n=7-14 mice per 
group.  Bar graphs not sharing a common letter are significantly different from one another 
(p<0.05). 
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Figure 3.10. CLD treatment does not rescue impaired glucose metabolism or insulin 
resistance and exacerbates adipose tissue insulin action.  After 20 weeks of diet/4 weeks of 
clodronate liposome treatment, metabolic outcomes were assessed: A) fasting (5 hour) 
blood glucose levels, B) fasting (5 hour) plasma insulin levels, C) intraperitoneal (IP) 
glucose tolerance test (GTT) and corresponding area under the curve (AUC), D) IP insulin 
tolerance test (ITT) following a 5-hour fast, E) serum free-fatty-acid (FFA) concentration 
following a 5-hour fast measured at the 0 and F) 30-minute time point of the ITT, and G) 
change in serum FFAs from 0-30 minutes of the ITT.  Values are means ± SE; n=9-15 mice 
per group.  Bar graphs not sharing a common letter are significantly different from one 
another (p<0.05). 
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Table 3.2.  CLD treatment results in anemia.  Whole blood collected at sacrifice (4 weeks 
after liposome treatment) was assessed for mean corpuscular hemoglobin concentration, as 
well as hemoglobin, and % hematocrit.  Values are means ± SE; n=9-15 mice per group.  
Groups not sharing a common letter differ significantly from one another (p<0.05).    
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CHAPTER 4 
 
SEX DISPARITIES IN OBESITY-ENHANCED COLON CANCER: 
DETRIMENT OF ADIPOSITY AND MACROPHAGE ASSOCIATED 
INFLAMMATION3 
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4.1 ABSTRACT 
Given the high prevalence of colorectal cancer (CRC) in the United States and the 
increased risk for of CRC in the obese population, it is important to understand the 
underlying mechanisms that link obesity to CRC.  Currently, there is increased incidence 
within obese males compared to obese females, and evidence suggests that female sex 
hormones may offer certain protection against obesity enhanced CRC.  In this study, MC38 
murine colon adenocarcinoma cells were injected subcutaneously (2x105cells/100L) in 
obese mice with associated metabolic dysfunctions following 20 weeks of high fat diet 
feeding to better elucidate the mechanisms behind tumor growth in an obese state.  This 
was performed in C57BL/6J males, females and females that underwent ovariectomy 
(OVX), in order to further examine the influence of female sex hormones in this obesity 
enhanced CRC model.  Our results indicate that enhanced tumor growth occurs following 
diet induced obesity and insulin resistance.  Among mice fed a high fat diet, OVX mice 
exhibited the most significant tumor growth compared to males and females (p=0.036 and 
0.001 respectively).  Furthermore, OVX mice presented with increased CD206 and 
decreased CD11c gene expression of macrophages isolated from tumors compared to those 
of female mice.  This increase in tumor growth and altered tumor associated macrophage 
phenotype were attributed to increased subcutaneous adipose tissue and adipose tissue 
inflammation present in the high fat diet OVX group following 20 weeks of diet feeding.  
This study provides evidence suggesting adiposity and macrophage associated adipose 
inflammation as potential mechanisms underlying female derived protection against 
obesity-associated CRC.   
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4.2 INTRODUCTION 
 It has been established that there is a positive relationship between obesity and 
CRC.  Obese men have a higher risk of CRC compared with normal weight men, but this 
association is much weaker in women [136]. On the other hand, postmenopausal women 
have an increased risk of obesity, insulin resistance and consequently have an increased 
incidence of CRC compared to premenopausal women [137, 138]. Interestingly, hormone 
replacement therapy (HRT), has been shown to reduce the risk of CRC in postmenopausal 
women although some studies have shown inconclusive effects [139].  
Epidemiological studies have shown that distribution of fat increases susceptibility 
to inflammation induced insulin resistance, which enhances CRC risk.  Although females 
have a larger proportion of body fat mass compared to males, the distribution of adipose 
tissue in males is primarily abdominal which is more closely linked to worsened insulin 
sensitivity [140]. Visceral adipose tissue, as opposed to subcutaneous or total body fat is 
presumed as the particular location for which these metabolic risk factors for CRC arise 
[141]. Furthermore, visceral adiposity correlates with increased circulating pro-
inflammatory adipokines, which can promote cellular proliferation, and angiogenesis 
[142].  This evidence suggests that adiposity, specifically location of adiposity, is strongly 
associated with obesity induced insulin resistance and CRC. 
This obesity associated inflammation is strongly influenced by immune cell 
populations, particularly macrophages present in the adipose tissue depots.  Studies by our 
laboratory (unpublished) show a sex-specific association of obesity with macrophage 
phenotype.  This data indicates that male mice have a significant increase in pro-
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inflammatory M1 macrophages in response to high fat diet whereas minimal increases are 
seen in female mice.  The ovariectomy of female mice results in increased M1 macrophages 
similar to males, which is reversed upon estrogen replacement.  This suggests that a 
combination of differential fat distribution and adipose tissue macrophage associated 
inflammation between men, women, and postmenopausal women may provide a 
mechanism for the differential incidence of CRC within those populations.   
Additional evidence supports a potentially protective role of estrogen against 
inflammation and obesity associated insulin resistance [143].  However, current literature 
does not provide a conclusive role for estrogen in CRC.  Further, there are few studies that 
have examined the role of estrogen in CRC in the settings of obesity.  This is largely due 
to the difficulties in choosing appropriate methods for either establishing obesity or 
inducing CRC.  Studies from our laboratory have shown that diet induced obesity increases 
the mucin production within the colon in the chemically induced AOM/DSS colon cancer 
model and thus affect the effectiveness of DSS induced inflammation to cause CRC [144]. 
Furthermore the transgenic ApcMin/+ mouse model for intestinal cancer is ineffective at 
testing obesity enhanced CRC because the genetic mutation of APC gene is present and 
expressed at birth. This results in development of intestinal polyps before obesity or 
associated metabolic dysfunctions can be established [113]. Due to these limitations in 
more commonly used CRC models, we utilized the subcutaneous MC38 tumor model, 
which allowed us to establish an obese phenotype with associated metabolic dysfunction 
prior to the initiation of cancer in order to better elucidate the mechanisms behind increased 
colon cancer risk in an obese population.  
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Given the high prevalence of CRC in the United States and the increased risk for 
of CRC in the obese population, it is important to elucidate the mechanistic link between 
obesity and CRC.  In this study, we examined adiposity and macrophage associated 
inflammation as potential mechanisms influencing sex disparities within colon derived 
tumor growth following diet-induced obesity.  
4.3 MATERIALS & METHODS 
Animals: Male and female WT C57BL/6J mice were purchased from the Jackson 
Laboratories (Bar Harbor, ME) and cared for at the Department of Laboratory Animal 
Resources at the University of South Carolina.  Mice (n=15/group) were housed 5 per cage, 
maintained on a 12:12-h light-dark cycle in a low stress environment (22°C, 50% humidity, 
low noise) and given water ad libitum.  Principles of laboratory animal care were followed, 
and the Institutional Animal Care and Usage Committee of the University of South 
Carolina approved all experiments.  At 9 weeks of age male mice underwent a sham surgery 
and female mice underwent either a sham or ovariectomy (OVX) surgery.  Briefly, mice 
underwent anaesthesia maintained with 2% isoflurane and oxygen before a dorsal incision 
was made to the skin then the muscle layers.  Both uterine horns were tied with non-
absorbable suture 5-0 (cat # S-G518R13) and ovaries were removed.  In case of the sham-
operated mice, the ovaries were exteriorized and then placed back intact into the abdominal 
cavity. The muscle wall was sutured with with 5-0 absorbable suture (cat # S-G518R13-
U) and wound clips were used to close skin incision. Buprenorphine was given as pain 
reliever subcutaneously at a dose of 0.043 mg/kg. Wound clips were removed 1 week after 
surgery and mice were allowed to recover for an additional week prior to initiation of diet 
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feedings.  The experiment was performed over 3 independent blocks, with n=5 
mice/group/block for a total of n=15/group. 
Diets: At 11 weeks of age, mice (Male, Female and OVX) were randomly assigned to 
either control purified AIN-76A low-fat diet (LFD) (3.77 kcal/g) or a purified HFD (40% 
of total kcals from fat; 4.57 kcal/g) designed to mimic the standard American diet (BioServ, 
Frenchtown, NJ, USA).  We have used this diet in several of our previous studies [50, 67, 
109-113].  Mice were initially provided the respective LFD or HFD for 20 weeks at which 
time baseline body composition (DEXA) and metabolic tests were performed.  Following 
MC38 colon cancer cell injection (described below), mice continued their respective diets 
(LFD or HFD) for another 3 weeks.  Thus, in total, mice consumed the assigned diets for 
23 weeks.  
Body weights, body composition and metabolism: Body weight was monitored on a weekly 
basis throughout the study.  Body composition was assessed before cancer cell injection at 
20 weeks of diet feeding.  For this procedure, mice were placed under brief anesthesia 
(isoflurane inhalation) and were assessed for lean mass, fat mass, body fat percentage and 
bone mineral density via dual-energy X-ray absorptiometry (DEXA) (Lunar PIXImus, 
Madison, WI).  Metabolic parameters were assessed at 20 weeks of dietary treatment.  After 
a five-hour fasting, blood samples were collected from the tip of the tail.  Blood glucose 
concentrations were determined in whole blood using a glucometer (Bayer Contour, 
Michawaka, IN).  Collected blood was centrifuged at 4,000 rpm for 10 min at 4°C.  Plasma 
was aliquoted and stored at -80°C until analysis.  Plasma insulin concentrations were 
analyzed using a mouse insulin ELISA kit according to the manufacturer’s instructions 
(Mercodia Inc., Winston Salem, NC).  Insulin resistance was estimated by HOMA index 
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according to the following formula: insulin resistance index = fasting insulin (μU/ml) x 
fasting glucose (mmol/l)/22.5.  For glucose tolerance tests (GTTs) and insulin tolerance 
tests (ITTs), mice were fasted for 5 hours and glucose or insulin was administered (IP) at 
a dose of 2 g/kg or 0.75 U/kg lean mass, respectively.  Blood glucose concentrations (tail 
sampling) were measured intermittently over a two-hour period (0, 15, 30, 60, 90, and 120 
minutes) for GTTs and intermittently over a one-hour period (0, 15, 30, 45, and 60 minutes) 
for ITTs using a glucometer (Bayer Contour, Michawaka, IN).  Area under the curve 
(AUC) was calculated using the trapezoidal rule.   
Subcutaneous Tumor Model: MC38, murine colon adenocarcinoma cells (Kerafast), were 
maintained in complete DMEM 4.5g/L glucose with 10% fetal bovine serum, 2mM 
glutamine, and 1% penicillin/streptomycin.  Cells were routinely passaged when 80% 
confluence was reached under sterile conditions and maintained in a 37°C, 5% CO2 
incubator.  Prior to injection, cells (passage <20) were trypsinized, washed, counted with 
a hemocytometer and resuspended at 2x106 cells/mL in phosphate buffered saline.  Mice 
were briefly anesthetized (isoflurane inhalation), and 100L of MC38 cell suspension 
(2x105cells/100L/mouse) was injected subcutaneously using a 0.3mL 29G syringe into 
the left dorsal lumbar region of each mouse.  Viability of the cell suspension was confirmed 
>95% using trypan blue staining before and after all injections were completed.  
Tissue collection: After 23 weeks of dietary treatment (3 weeks after tumor injection), mice 
were sacrificed via isoflurane inhalation for tissue collection.  Whole blood taken from the 
inferior vena cava was analyzed for hematology analysis using a VetScan Hm5 (Abaxis, 
Union City, CA).  The blood was spun at 4,000 RPM x 10 min and aliquoted plasma was 
stored -80°C.  Gonadal, mesentery, and peri-renal fat pads, as well as the liver and spleen 
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were removed, weighed, and immediately snap-frozen in liquid nitrogen and stored at 
−80°C until analysis.  Subcutaneous tumors were removed, weighed and measured (length 
and width) using calipers.  Half of the tumor was placed in complete DMEM to be used for 
cell sorting.  The other half was snap frozen and stored at -80°C until analysis. 
Flow Cytometry and Cell Sorting: Tumors were mechanically disrupted in PBS with 5% 
FBS using the gentleMACS dissociate and tumor associated macrophages (TAMs) were 
isolated using FACS as described [145]. Briefly tumor isolates underwent RBC lysis and 
filtered through a 100M then 70M cell strainer prior to being stained with CD45-APC, 
F4/80-PE, and CD11b-FITC (Biolegend, San Diego, CA) antibodies for 30 minutes.  
Following compensation using unstained and single stained controls, tumor associated 
macrophages were quantified by gating for CD45+ cells followed by F480 and CD11b 
double positive gate.  TAMs were sorted into a separate tube containing PBS with 5% FBS 
and kept on ice until all samples were sorted.  Data were acquired using a BD FACS Aria 
II cell sorter and analyzed using DIVA software.  Freshly sorted TAMs were spun at 2000 
RPM x 5min, resuspended in trizol reagent and stored at -20⁰C until RNA isolation. 
Quantitative real-time RT-PCR:  RNA was isolated from fluorescent activated cell sorted 
TAMs, and gonadal and subcutaneous adipose tissue depots using trizol reagent.  TaqMan 
reverse transcription reagents and gene expression assays (Applied Biosystems, Foster 
City, CA) were used to reverse transcribe and to analyze the expression of the following 
genes: F4/80, CD11c, CD206, MCP-1, NOS, ARG, TNFα, and TGFβ. Potential reference 
genes (18s, HMBS, TBP, B2M, H2AFV, and HPRT) were analyzed for stability using 
Qbase+ software (Biogazelle, Belgium) for each tissue analyzed. The optimal number of 
reference genes were determined by Qbase+ and the geometric mean of these genes was 
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used as the normalization factor for each analysis: TAM (B2M and H2AFV), gonadal 
adipose tissue (H2AFV, 18S, HPRT, HMBS, TBP), and subcutaneous adipose tissue 
(B2M, TBP, HMBS) [50, 119].  Gene expression quantification was calculated using the 
ΔΔCT method and Qbase+ software.  Values were normalized to the LFD female group.  
Micro Computed Tomography (CT) Quantification of Fat Volume: Following 20 weeks of 
diet feeding mice were placed under brief anesthesia (isoflurane inhalation) and positioned 
with both legs fully extended on the bed.  The torso was scanned at an isotropic voxel size 
of 44 mm FOV (70kVp, 114uA) for 18seconds using Quantum GX micro CT Imaging 
System (Perkin Elmer).  Using, AccuCT micro CT analysis software, all scans were 
calibrated to Hounsfield Unites (HU) based on the standard densities of plastic (40) and air 
(-1000) plotted against the measured density at the time of scanning.  All scans underwent 
low pass filter to remove background noise and cropped to a region of interest between L1 
and L5 of each mouse.  Threshold objects of bone (>500 HU), soft tissue (75-500 HU) and 
adipose tissue (<75 HU) were applied to all scans.  Subcutaneous and visceral adipose 
tissue was differentiated using the abdominal wall as an anatomical landmark (adipose 
superficial to the soft tissue layer was marked subcutaneous and all adipose deep marked 
as visceral).  Volumes of specified objects (bone, soft tissue, visceral fat and subcutaneous 
fat) were calculated using AccuCT micro CT analysis software.  Volumes of adipose tissue 
were then normalized to the soft tissue volume calculated within each scan [146].  
Statistical Analysis: Data were analyzed using commercially available statistical software: 
Prism 6 (GraphPad Software, La Jolla, CA).  A two-way ANOVA followed by a turkey 
post-hoc analysis was used to determine differences between diet (HFD vs. LFD) and 
hormone status (female intact estrogen+/testosterone-; female OVX estrogen-
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/testosterone-; and male estrogen-/testosterone+).  For correlation calculations values were 
plotted on an XY plot and a Pearson correlation was performed with a two tailed 95% 
confidence interval and significance set to p<0.05. Any statistical test that did not pass the 
equal-variance test (Bartlett’s test for equal variances) was log transformed and then re-
analyzed.  Data are presented as the mean ± SEMs and the level of significance was set at 
p<0.05.  
4.4 RESULTS 
20 weeks of HFD feeding leads to an obese phenotype that is exacerbated in male and OVX 
mice 
At 9 weeks of age mice received either a sham or ovariectomy surgery to establish 
male, female, or OVX groups.  Two weeks following surgery, mice were fed a 40% HFD 
or a purified LFD for 20 weeks.  An obese phenotype was successfully achieved as the 
HFD-fed mice gained significantly more body weight, fat mass, and displayed a 
significantly greater body fat % (Figure 4.1 A-B) compared to LFD fed mice (p<0.05).  
HFD-fed mice also displayed elevated fasting blood glucose, insulin, HOMA-Index, GTT 
AUC, and impaired insulin sensitivity (Figures 4.1 D-J), demonstrating a dysfunctional 
metabolic phenotype (p<0.05).  Further, within a high fat diet, male mice exhibited 
increased body fat mass (p=0.01), lean mass (p<0.0001) and HOMA-Index (p<0.0001) 
compared to intact female mice, indicating that females exhibit a slight protection against 
diet induced obesity.  However, this observed protection was not as prevalent in the HFD 
OVX group, which exhibited increased body weight and fat mass (p<0.0001) with trending 
increased body fat%, GTT, and HOMA-index although these were not significantly 
increased compared to HFD females.  Further, this OVX group resulted in decreased bone 
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mineral density compared to intact females or males, independent of diet, a common 
consequence of estrogen depletion as estrogen is important for bone calcium reabsorption 
(Figure 4.1 C).  
Tumor weight is increased in obese mice and is most severe in HFD OVX group 
Following MC38 cell injection, tumors were allowed to grow for 3 weeks before 
weights were measured.  Consistent with epidemiological evidence, HFD resulted in 
increased tumor weight compared to LFD (Figure 4.2 A).  This was consistent with 
increases in spleen and liver weight of the HFD mice compared to LFD (Figure 4.2 B-C).  
As expected, adipose tissue of all depots measured was significantly increased as a result 
of 23-week HFD feeding (Figure 4.2 E).  Additionally, HFD feeding significantly increased 
white blood cells, specifically lymphocytes and neutrophils within whole blood (Figure 4.2 
F).  Interestingly, the HFD OVX group presented with the largest tumors of any group, 
significantly larger compared to female and male groups within the same diet treatment 
(Figure 4.2 A p=0.036 and 0.001 respectively).  This increase in tumor weight within HFD 
OVX was consistent with increased white blood cells, specifically neutrophils (p=0.005) 
(Figure 4.2 F).  However, contrary to the epidemiological data, HFD feeding in male mice 
did not significantly increase tumor weight.  Further, the tumor challenge resulted in 
reduced gonadal adipose tissue and subsequent total adipose weights measured 3 weeks 
following tumor initiation compared to female and OVX mice within the same diet 
(p<0.0001) (Figure 4.2 E).  Despite the reduced tumor weight and gonadal adipose tissue, 
HFD male mice presented with increased white blood cells, specifically lymphocytes and 
neutrophils, similar to the HFD OVX mice.  The phenotypic differences between female 
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and OVX groups were further confirmed by significant decreases in uterus weight of the 
OVX groups compared to the female groups (p<0.0001) as shown in figure 4.2 D.  
Tumor associated macrophages isolated from female and OVX tumors exhibited different 
phenotypes 
Due to the unchanged tumor growth observed in the lean compared to obese male 
mice, we decided to focus on the interaction solely between female intact and OVX mice 
within respective diets.  Following tumor excision, TAMs were defined as double positive 
F4/80 and CD11b cells from a CD45 positive gate and were collected using FACS (Figure 
4.3 A).  Although there were differences in tumor weight as seen in Figure 4.2 A, between 
HFD OVX and female mice, there were no significant differences in the TAM percentage 
within these tumors (Figure 4.3 B).  However, upon further investigation of the gene 
expression in these isolated TAMs, CD11c, an M1 macrophage marker was significantly 
increased in female mice (p=0.05), consistent with a significant decrease in expression of 
CD206, an M2-macropahge marker (p=0.02) (Figure 4.3 C-D).  This indicates that 
irrespective of tumor size or diet, female mice possess more pro-inflammatory/ anti-tumor 
macrophages within the tumor microenvironment compared to OVX mice.  However, 
because TAMs were isolated from tumors of different sizes it is unclear whether this altered 
macrophage phenotype directly impacted tumor growth or is simply a consequence of the 
difference in tumor size.  
Spleen, total fat and fasting insulin levels are positively correlated with tumor weight of 
female and OVX mice. 
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In order to further examine potential mechanisms of the increased tumor size within 
OVX mice, tumor weight was plotted against spleen, total fat and fasting insulin levels 
(Figure 4.4).  Consistent with other cancer models, tumor size was strongly correlated with 
increased spleen size (R2=0.6017, p<0.0001), confirming that an increased immune 
response is present following tumor challenge.  Additionally, there was a significant 
positive, albeit weak, correlation between total visceral fat (R2=0.294, p=0.0008) compared 
to tumor weight as well as fasting plasma insulin levels (R2=0.4151, p<0.0001) compared 
to tumor weight suggesting a potential link between fat distribution or insulin sensitivity 
and tumor growth.  
Differential fat distribution of visceral and subcutaneous fat among female and OVX mice 
following 20-week diet feedings 
The significant correlation between tumor weight and total fat shown in Figure 4.4 
B, led us to initiate a new cohort of female and OVX mice subjected to the same low fat or 
high fat diet treatment for 20 weeks. This helped us understand the environment at the time 
of MC38 injection as opposed to 3 weeks following tumor growth. As reflected in the 
DEXA analysis in the previous study (Figure 4.1B), 20 weeks of HFD feeding resulted in 
significantly increased body fat %.  Although within the HFD, no difference in body fat % 
was observed between OVX and female mice.  To better understand distribution of fat 
rather than total body fat%, the new cohort of mice were scanned using micro CT which is 
considered more accurate and sensitive than DEXA and can distinguish between visceral 
and subcutaneous fat [146]. As seen in the representative images in Figure 4.5 A, bone, 
soft tissue, visceral fat and subcutaneous fat were able to be distinguished based on 
differing densities, and quantified by volume within the region of interest, L1 and L5.  The 
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micro CT analysis in Figure 4.5 B-C, confirmed, that in addition to increased visceral 
adipose tissue, HFD mice had significantly increased subcutaneous adipose tissue 
compared to LFD mice (p<0.0001).  Further, OVX mice had significantly increased 
subcutaneous fat distribution compared to female mice within either LFD or HFD groups 
(p=0.04 and p=0.03, respectively).  In order to confirm the accuracy of the micro CT 
analysis to measure adipose volume, a correlation between visceral adipose tissue weight 
taken at sacrifice and visceral adipose volume calculated via micro CT scan revealed a 
strong positive correlation (R2= 0.9793 and p<0.0001) (Figure 4.5 D).  
Increased macrophage infiltration and associated inflammation in adipose tissue of HFD 
OVX mice 
As expected, a main effect of diet was achieved through increased F480, MCP1, 
CD11c, CD206, NOS, ARG-1, TNF and TGFβ gene expression within HFD parametrial 
adipose tissue compared to LFD adipose tissue (p<0.05) (Figure 4.6).  Additionally, within 
the HFD group, OVX mice presented with greater adipose inflammation with significant 
increased F480, MCP1, CD11c, CD206, NOS, ARG-1, TNF and TGFβ compared to 
female mice (p<0.01).  This severe inflammation presented only in the adipose tissue of 
HFD OVX mice, supporting that intact female mice are to a certain extent protected against 
obesity induced adipose tissue inflammation.  The subcutaneous adipose tissue gene 
expression revealed no significant difference in F4/80 macrophage gene expression in 
contrast to a significant increase in MCP-1 within HFD compared to LFD (p=0.01).  
Among HFD fed mice, OVX mice had significantly increased MCP-1 concentrations 
compared to female (p=0.05).  Additionally, OVX mice displayed a significant increase in 
the pro-inflammatory macrophage marker CD11c compared to female mice within HFD 
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(p=0.001).  These differences indicate that inflammation is unique within visceral and 
subcutaneous adipose tissue depots and that HFD OVX mice have greater adipose tissue 
inflammation compared to HFD female mice.  
 
4.5 DISCUSSION 
Given the established link between obesity and CRC along with a suggested 
interaction of sex specific hormones, we examined sex disparities within colon derived 
cancer growth following diet-induced obesity.  Using the subcutaneous MC38 tumor 
model, we were able to replicate some epidemiological data, as we observed enhanced 
tumor growth following diet-induced obesity and insulin resistance.  Within female mice 
on a high fat diet, some protection against obesity-enhanced tumor growth was observed 
compared to ovariectomized mice.  However, male mice failed to coincide with 
epidemiological data and did not exhibit increased tumor growth compared to females fed 
the same diet.  It was revealed in a follow up study, that following 20 weeks of high fat 
diet feeding, OVX mice had significantly increased visceral and subcutaneous fat 
compared to female mice.  These adipose tissue depots within HFD OVX exhibited more 
severe macrophage associated inflammation through observed increases in CD11c, M1 
macrophage gene expression.  Taken together these data suggest that accelerated 
subcutaneous tumor growth within obese OVX mice may be due to the increase in 
subcutaneous adiposity combined with increased M1, pro-inflammatory adipose tissue 
macrophages.  
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The association between obesity and CRC has been suggested in both 
epidemiological and in-vivo mouse studies.  Epidemiological evidence has further 
uncovered a more significant relationship in men than in women [42-44].  A meta-analysis 
of 18 observational studies showed a 20% reduction in colon cancer incidence among 
women who had ever used HRT, indicating a specific association between female sex 
hormones and CRC [47]. Utilizing in-vivo subcutaneous tumor models, many have 
reported that obesity enhances colorectal tumor growth [147-150].  Consistent with our 
findings, Yakar et al, revealed similar increases in tumor growth of obese OVX mice 
compared to female mice [137].  However, contrary to what we found, this group was able 
to show obesity-enhanced tumor growth in males in addition to female and OVX mice 
although they did not directly compare all 3 groups within the same experiment [150]. Our 
study is the first to include male, female and OVX mice in an obesity-enhanced 
subcutaneous tumor model in order to directly examine sex disparities within this cancer 
model.  
Although there is evidence to support sex differences in obesity enhanced CRC, a 
clear mechanism has yet to be elucidated.  Macrophage associated inflammation has been 
implicated in obesity induced insulin resistance and CRC which may offer an explanation 
for the large tumors present in HFD OVX mice.  We observed that in addition to large 
tumors, HFD OVX mice presented with more pro-inflammatory macrophages within both 
the visceral and subcutaneous adipose tissue depots.  M1 macrophage derived 
inflammatory cytokines, including NOS and TNF- which were both increased in our HFD 
OVX parametrial adipose tissue, can activate the inflammatory pathways NFB and 
STAT3 to mediate proliferation, invasion, angiogenesis, survival and metastasis [151, 
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152]. This is consistent with our findings that pro-inflammatory adipose tissue 
macrophages present at the time of MC38 injection in HFD OVX mice may have resulted 
in the increased tumor weight that was observed 3 weeks post injection.  
In addition to inflammation, distribution of adiposity may play an important role in 
colon carcinogenesis [153].  In the present study, utilizing highly accurate micro CT 
analysis, we found increased visceral and subcutaneous adipose tissue within HFD OVX 
mice compared to female mice.  There is emerging evidence that adipose stromal cells may 
be a source of stromal cells in tumor microenvironments.  In animal models of obesity, 
adipose stromal cells from inflamed visceral adipose tissue can migrate to tumor sites 
[154]. These, stromal cells present in the tumor microenvironment can promote 
angiogenesis and support tumor progression[18]. This offers evidence that increased 
adiposity within HFD OVX mice may have resulted in increased adipose derived stromal 
cells in the tumor and these stromal cells promoted tumor growth.  However additional 
studies are necessary to confirm this hypothesis.  
There is some evidence that female sex hormones may offer a protection against 
CRC.  In vitro findings have shown that estradiol in addition to estrogen receptor  agonist 
can inhibit proliferation and migration of MC38 cells [155, 156].  In several in-vivo studies, 
exposure of ovariectomized rats to estrogen reduced the rate of colon tumors by 71% [138, 
157].  In addition, in the ApcMin/+ mice ovariectomy resulted in an increased number of 
polyps, whereas estrogen replacement in these mice reduced the number of polyps to the 
baseline levels [158]. Our data is consistent with these findings, as the female mice 
presented with smaller tumors compared to ovariectomized mice.  Moreover, the tumor-
associated macrophages within female tumors had higher expression of CD11c with 
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reduced expression of CD206 compared to OVX mice.  This shift in the M1/M2 like TAM 
ratio suggests a more tumoricidal environment that coincides with the reduced tumor size 
of female mice.  Taken together our results indicate a potential for sex hormones present 
in females to influence tumor growth and TAM phenotype.  
In addition to macrophage associated inflammation, adiposity and estrogen 
influencing CRC, emerging evidence indicates insulin as a mechanism for cancer 
proliferation.  Obesity leads to insulin resistance and results in increased circulating insulin.  
A proliferative role of insulin has been reported in various cancers including breast cancer, 
pancreatic cancer and CRC [159, 160].  Hvid et al, reports that treatment with insulin 
accelerates tumor growth, specifically in the MC38 subcutaneous tumor model [161]. 
Additionally reducing circulating insulin levels may be beneficial in cancer prevention, as 
treatment with metformin, a type 2 diabetes drug, is associated with reduced incidence of 
breast cancer in women [162]. Consistent with primary literature, we report a positive 
correlation between tumor weight and fasting insulin levels in female and OVX mice, 
although we did not explore this potential mechanism further in this study.  
An unexpected finding that conflicts with the previously stated evidence was that 
tumor growth in HFD males was not increased compared to LFD males despite the 
significantly high level of fasting insulin.  One possible explanation could be that in 
addition to fasting insulin levels, macrophage infiltration and pro-inflammatory 
macrophages in the adipose tissue of obese male mice were also significantly increased 
compared to both the OVX and female mice within the high fat diet (data not shown).  
Although chronic low-grade inflammation is often cancer promoting, perhaps severe acute 
inflammation induces apoptosis.  It is possible that the chronic mild inflammatory 
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environment of the high fat diet OVX mice combined with the high levels of circulating 
insulin was conducive to cancer growth while the severe inflammation in the male mice 
offset any proliferative effects of the increased circulating insulin.  Of course, additional 
studies, involving insulin, insulin knockout mice, or insulin antagonists would be required 
in order to test this hypothesis. 
In conclusion, our study confirms that obesity enhanced CRC was achieved 
following 20 weeks of a high fat diet using a subcutaneous MC38 tumor model, thus 
validating this model for future studies.  We established that diet induced obesity and 
associated insulin resistance present differently in male, female and OVX mice.  
Additionally, increased accumulation of subcutaneous fat and increased pro-inflammatory 
adipose tissue macrophages at the time of tumor challenge, are likely responsible for the 
accelerated tumor growth observed in the high fat diet OVX mice.  This study provides 
insight into potential mechanisms behind female associated protection against obesity 
associated CRC.  
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4.6 FIGURES & LEGENDS 
 
 
Figure 4.1 Body composition and metabolic assessment after 20 weeks of dietary treatment 
prior to injection of MC38 cells.  A) Mouse body weight, B-E) body composition, fat mass, 
lean mass, fat%, and bone mineral density, respectively F-G) intraperitoneal (IP) glucose 
tolerance test (GTT) and corresponding area under the curve (AUC), H-I) IP insulin 
tolerance test (ITT) following a 5-hour fast and corresponding AUC. J) fasting (5 hour) 
blood glucose levels, K) fasting (5 hour) plasma insulin levels, L) Homeostatic Model 
Assessment Index – Insulin Resistance (HOMA‐IR) calculated as fasting insulin (μU/ml) 
x fasting glucose (mmol/l)/22.5.  Values are means ± SE; n=12-15 mice per group.  Bar 
graphs not sharing a common letter are significantly different from one another (p<0.05).  
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Figure 4.2 High fat diet feeding increased tumor weight with enhance growth in OVX 
group.  A) Tumor weight measurements 3 weeks post injection B-D) Organ weights of 
spleen, liver, and uterus (females only), respectively.  E) Weight of various adipose depots 
with total fat as the sum of gonadal, mesentery and kidney weights.  F) Complete blood 
count of whole blood.  Values are means ± SE; n=9-15 mice per group.  Bar graphs not 
sharing a common letter are significantly different from one another (p<0.05)  
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Figure 4.3 Differential tumor associated macrophage phenotype in female and OVX 
groups.  A) Representative gating strategy for collection of tumors associated 
macrophages, defined as CD45+ F4/80+ CD11b+ cells.  B) Percentage of tumor associated 
macrophages within tumors at time of sort.  C-D) Quantitative RT-PCR assessment of gene 
expression in sorted tumor associated macrophages.  Ct values relative to average of 
multiple internal controls determined using qBASE pro software analysis.  Values are 
means ± SE; n=3-4 mice per group.  Bar graphs not sharing a common letter are 
significantly different from one another (p<0.05) 
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Figure 4.4 Tumor weight positive correlated with spleen, fat and fasting insulin levels 
among female and OVX mice.  Correlation between tumor weight and A) spleen weight, 
B) total fat weight, C) fasting insulin from plasma.  Data analyzed using Pearson 
correlation set to 95% confidence two tailed with significance set to <0.5)   
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Figure 4.5 Micro CT imagining of mice at 20weeks DIO reveals differential fat 
distribution.  A) Representative micro CT images of defined objects based on density 
thresholds, bone, soft tissue, visceral fat, subcutaneous fat, B-C) Quantification of adipose 
volume based on defined objects within micro CT scans.  Volumes relative to soft tissue 
volumes, D) Pearson Correlation between quantified volume of visceral adipose tissue via 
micro CT and visceral adipose tissue weight taken at sacrifice.  Values are means ± SE; 
n=8-9 mice per group.  Bar graphs not sharing a common letter are significantly different 
from one another (p<0.05)  
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Figure 4.6 Gene expression of macrophage markers and associated inflammation in 
parametrial adipose tissue.  Relative gene expression of F480, MCP-1, CD11c, NOS, TNF, 
CD206, ARG, TGF of mRNA isolated from parametrial adipose tissue.  Ct values relative 
to average of multiple internal controls determined using qBASE pro software analysis.  
Values are means ± SE; n=8-9 mice per group.  Bar graphs not sharing a common letter 
are significantly different from one another (p<0.05) 
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Figure 4.7 Gene expression of macrophage markers and associated inflammation in 
subcutaneous adipose tissue.  Relative gene expression of F480, MCP-1, CD11c, NOS, 
TNF, CD206, ARG, TGF of mRNA isolated from the dorsal-lumbar portion of the inguinal 
adipose tissue.  Ct values relative to average of multiple internal controls determined using 
qBASE pro software analysis.  Values are means ± SE; n=8-9 mice per group.  Bar graphs 
not sharing a common letter are significantly different from one another (p<0.05) 
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CHAPTER 5 
SUMMARY AND CONCLUSIONS 
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Macrophages play a variety of roles during the development of chronic 
inflammation and are a driving force behind inflammation induced insulin resistance and 
inflammation association CRC.  There is further evidence to support that sex disparities 
within these inflammatory diseases may be in part associated with the influence of sex 
hormones on macrophage behavior.  In the present study, I have examined the effect of 
eliminating macrophage associated inflammation in either the context of CRC or obesity 
as a potential therapeutic treatment for these inflammatory driven diseases.  I have also 
uncovered a possible mechanism for sex disparities within obesity enhanced CRC 
attributed to differential fat distribution and adipose inflammation. 
 As presented in my first study, reducing macrophages using clodronate 
encapsulated liposomes during the late stage of the chemically induced AOM/DSS CRC 
model, was effective at a reducing both colon polyp number and size compared to vehicle 
treated AOM/DSS mice.  Although clodronate was not able to rescue tumor grade, through 
histopathological evaluation of dysplasia or disease symptom scores.  This reduction in 
colon polyp number was attributed to reduced colon macrophages, in particular pro-
tumoral TAM cytokines.  Consistently, there was reduced activation of oncogenic 
proliferation pathways including p38, ERK and STAT3 observed in the colon of 
macrophage depleted mice.  Lastly, macrophage depleted mice, presented with a unique 
gut microbiota composition rich in beneficial, butyrate producing flora.  This study 
concluded that in the late stages of CRC, TAMs predominate, and that decreasing these 
macrophages and associated cytokines through CLD-liposomes resulted in a reduced 
diseased state with improved outcome.  
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 Conversely, in the context of the inflammatory driven disease obesity, depletion of 
macrophages resulted in a compensatory reaction that exacerbated and worsened the 
disease state.  This rationale that if macrophage depletion is in fact beneficial in late stage 
CRC perhaps, it would offer similar benefits in obesity associated insulin resistance, since 
insulin resistance is closely linked to CRC.  However, depletion of adipose tissue 
macrophages, following diet induced obesity, was ineffective at rescuing obesity 
associated metabolic function.  In fact, macrophage depletion exacerbated inflammation 
and resulted in neutrophilia observed through increased adipose tissue and circulating 
neutrophils.  We concluded that in the absence of macrophages during the obese state, 
neutrophils infiltrate into the adipose tissue in response to MCP1, exacerbating tissue 
specific and systemic inflammation.  This compensatory reaction therefore negates any 
potential benefit of macrophage depletion in the context of obesity.  These results highlight 
the importance of macrophage presence within adipose tissue and encourage therapies that 
specifically target macrophage associated inflammation without affecting macrophage 
number. 
 Lastly, in Chapter 4, we used mouse models of obesity and CRC, to examine 
macrophage associated inflammation on obesity enhanced CRC with respect sex 
disparities.  It was observed that high fat diet feeding accelerated tumor growth with HFD 
OVX exhibiting the largest tumors.  We proposed that this increase in tumor growth in the 
OVX group is related to increased adiposity and macrophage associated inflammation 
within the adipose tissue.  Although, these results did not completely agree with 
epidemiological data, they were able to uncover sex differences in adipose tissue 
distribution and macrophage associated adipose inflammation.  This study provides insight 
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into potential mechanisms underlying protection of females against obesity associated 
CRC.  
 Taken together, these data suggest that macrophages differentially impact obesity 
and CRC.  While clodronate mediated macrophage depletion may not provide a global 
treatment for all inflammatory driven diseases, it provided further insight into the diverse 
functions of macrophages in the context of obesity and CRC.  Additionally, a potential 
mechanism for sex-disparities in CRC may involve macrophage associated inflammation.  
Due to the prevalence of obesity and CRC worldwide, any evidence that suggests potential 
mechanisms for these inflammatory driven diseases are profoundly important.  However, 
further studies are needed to explore therapies targeting macrophage associated 
inflammation in obesity and CRC. 
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CHAPTER 6 
FUTURE DIRECTIONS 
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In these studies, we focused primarily on the progression of CRC or diet-induced 
obesity in the absence of macrophages in order to better understand the role of 
macrophages in these diseases.  Although it was effective at depleting macrophages, 
clodronate treatment resulted in significantly decreased food intake of mice.  In order to 
confirm that the results we observed in chapters 2 and 3 were specifically related to 
macrophage depletion and not the clodronate treatment, it would be important to further 
test our hypotheses using an alternative method to deplete macrophages.  Further, given 
the differential importance of macrophage phenotype in obesity and CRC, it would be 
interesting to focus our approach by targeting macrophage subsets or tissue specific 
macrophages rather than total macrophages.  Although specific M1 or M2 targeted 
macrophage depletions are difficult, the utilization of LysM Cre- crossed with a loxP site 
targeted to NOS or ARG, the common M1 and M2 expressing macrophage gene, 
respectively, could prove effective at phenotype specific targeting within either the obesity 
or CRC models previously used. 
Our results in Chapter 4 indicate that sex specific differences are observed in an 
obesity enhanced tumor model and that macrophage associated inflammation may play a 
role.  It would be important to follow up this study to include the addition of both an 
estrogen and progesterone to further validate our hypothesis that female sex hormones offer 
some protection.  Additionally, emerging evidence supports the influence of insulin in 
tumorigenesis and cancer risk.  Targeting insulin, either through addition of insulin, insulin 
inhibitors or by transfecting the MC38 cells to become insulin receptor deficient would 
offer a more mechanistic approach to examine insulin specific effects on tumorigenesis.
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